Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,34268908,AUC0-72h,"Hydroxychloroquine AUC0-72h and Cmax did not differ between groups without and with pantoprazole (arithmetic mean; AUC0-72h , 7649 ng/ml • h, and 8429 ng/ml • h, P = .50; Cmax , 448 ng/mL and 451.5 ng/mL, P = .96, respectively).",Effect of Pantoprazole on the Absorption of Hydroxychloroquinea A Randomized Drug-Drug Interaction Trial in Healthy Adults. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34268908/),[ng] / [h·ml],7649,4157,DB00213,Pantoprazole
,34268908,AUC0-72h,"Hydroxychloroquine AUC0-72h and Cmax did not differ between groups without and with pantoprazole (arithmetic mean; AUC0-72h , 7649 ng/ml • h, and 8429 ng/ml • h, P = .50; Cmax , 448 ng/mL and 451.5 ng/mL, P = .96, respectively).",Effect of Pantoprazole on the Absorption of Hydroxychloroquinea A Randomized Drug-Drug Interaction Trial in Healthy Adults. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34268908/),[ng] / [h·ml],8429,4158,DB00213,Pantoprazole
,34268908,Cmax,"Hydroxychloroquine AUC0-72h and Cmax did not differ between groups without and with pantoprazole (arithmetic mean; AUC0-72h , 7649 ng/ml • h, and 8429 ng/ml • h, P = .50; Cmax , 448 ng/mL and 451.5 ng/mL, P = .96, respectively).",Effect of Pantoprazole on the Absorption of Hydroxychloroquinea A Randomized Drug-Drug Interaction Trial in Healthy Adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34268908/),[ng] / [ml],448,4159,DB00213,Pantoprazole
,34268908,Cmax,"Hydroxychloroquine AUC0-72h and Cmax did not differ between groups without and with pantoprazole (arithmetic mean; AUC0-72h , 7649 ng/ml • h, and 8429 ng/ml • h, P = .50; Cmax , 448 ng/mL and 451.5 ng/mL, P = .96, respectively).",Effect of Pantoprazole on the Absorption of Hydroxychloroquinea A Randomized Drug-Drug Interaction Trial in Healthy Adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34268908/),[ng] / [ml],451.5,4160,DB00213,Pantoprazole
,32110830,concentration,"Patients with no PPI had no significant difference in plasma voriconazole concentration when compared with those with PPI (2.63 ± 2.13 μg/mL [95% confidence interval {CI} 1.57-3.69] vs 2.11 ± 1.73 μg/mL [95%CI 1.67-2.55], P > .05).",A multicentre prospective study evaluating the impact of proton-pump inhibitors omeprazole and pantoprazole on voriconazole plasma concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32110830/),[μg] / [ml],2.63,14376,DB00213,Pantoprazole
,32110830,concentration,"Patients with no PPI had no significant difference in plasma voriconazole concentration when compared with those with PPI (2.63 ± 2.13 μg/mL [95% confidence interval {CI} 1.57-3.69] vs 2.11 ± 1.73 μg/mL [95%CI 1.67-2.55], P > .05).",A multicentre prospective study evaluating the impact of proton-pump inhibitors omeprazole and pantoprazole on voriconazole plasma concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32110830/),[μg] / [ml],2.11,14377,DB00213,Pantoprazole
,32110830,plasma concentration,"However, voriconazole plasma concentration was significantly lower in patients treated with pantoprazole vs those treated with omeprazole (1.44 ± 1.22 μg/mL [95%CI 0.94-1.94) vs 2.67 ± 1.88 μg/mL [95%CI 2.02-3.32], P = .013) suggesting a greater CYP2C19 enzyme inhibitory effect of omeprazole.",A multicentre prospective study evaluating the impact of proton-pump inhibitors omeprazole and pantoprazole on voriconazole plasma concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32110830/),[μg] / [ml],1.44,14378,DB00213,Pantoprazole
,32110830,plasma concentration,"However, voriconazole plasma concentration was significantly lower in patients treated with pantoprazole vs those treated with omeprazole (1.44 ± 1.22 μg/mL [95%CI 0.94-1.94) vs 2.67 ± 1.88 μg/mL [95%CI 2.02-3.32], P = .013) suggesting a greater CYP2C19 enzyme inhibitory effect of omeprazole.",A multicentre prospective study evaluating the impact of proton-pump inhibitors omeprazole and pantoprazole on voriconazole plasma concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32110830/),[μg] / [ml],2.67,14379,DB00213,Pantoprazole
,9799054,AUC,"Geometric means of AUC (extent characteristic) and Cmax/AUC (rate characteristic) of carbamazepine were 292 and 287 mgxh/l, and 0.0150 and 0.0144 l/h (reference and test), respectively.",Pantoprazole does not interact with the pharmacokinetics of carbamazepine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9799054/),[h·mg] / [l],292,20854,DB00213,Pantoprazole
,9799054,Cmax/AUC,"Geometric means of AUC (extent characteristic) and Cmax/AUC (rate characteristic) of carbamazepine were 292 and 287 mgxh/l, and 0.0150 and 0.0144 l/h (reference and test), respectively.",Pantoprazole does not interact with the pharmacokinetics of carbamazepine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9799054/),[h·mg] / [l],287,20855,DB00213,Pantoprazole
,9799054,Cmax/AUC,"Geometric means of AUC (extent characteristic) and Cmax/AUC (rate characteristic) of carbamazepine were 292 and 287 mgxh/l, and 0.0150 and 0.0144 l/h (reference and test), respectively.",Pantoprazole does not interact with the pharmacokinetics of carbamazepine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9799054/),[l] / [h],0.0150,20856,DB00213,Pantoprazole
,9799054,Cmax/AUC,"Geometric means of AUC (extent characteristic) and Cmax/AUC (rate characteristic) of carbamazepine were 292 and 287 mgxh/l, and 0.0150 and 0.0144 l/h (reference and test), respectively.",Pantoprazole does not interact with the pharmacokinetics of carbamazepine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9799054/),[l] / [h],0.0144,20857,DB00213,Pantoprazole
,9799054,rate characteristic,"Geometric means of AUC (extent characteristic) and Cmax/AUC (rate characteristic) of carbamazepine were 292 and 287 mgxh/l, and 0.0150 and 0.0144 l/h (reference and test), respectively.",Pantoprazole does not interact with the pharmacokinetics of carbamazepine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9799054/),[l] / [h],0.0144,20858,DB00213,Pantoprazole
,27611887,eradication rate,"Among patients appearing for follow-up examination (n = 105), the eradication rate for H. pylori was 82.8% (n = 87).",Effects of Genetic Polymorphisms of Cytochrome P450 Enzymes and MDR1 Transporter on Pantoprazole Metabolism and Helicobacter pylori Eradication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27611887/),%,82.8,30713,DB00213,Pantoprazole
,27611887,plasma concentrations,"The median pantoprazole plasma concentrations in poor metabolizers (PM), rapid metabolizers (RM) and ultrarapid metabolizers (URM) were 2.07, 1.69 and 1.28 μg/ml, respectively (p = 0.04).",Effects of Genetic Polymorphisms of Cytochrome P450 Enzymes and MDR1 Transporter on Pantoprazole Metabolism and Helicobacter pylori Eradication. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27611887/),[μg] / [ml],2.07,30714,DB00213,Pantoprazole
,27611887,plasma concentrations,"The median pantoprazole plasma concentrations in poor metabolizers (PM), rapid metabolizers (RM) and ultrarapid metabolizers (URM) were 2.07, 1.69 and 1.28 μg/ml, respectively (p = 0.04).",Effects of Genetic Polymorphisms of Cytochrome P450 Enzymes and MDR1 Transporter on Pantoprazole Metabolism and Helicobacter pylori Eradication. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27611887/),[μg] / [ml],1.69,30715,DB00213,Pantoprazole
,27611887,plasma concentrations,"The median pantoprazole plasma concentrations in poor metabolizers (PM), rapid metabolizers (RM) and ultrarapid metabolizers (URM) were 2.07, 1.69 and 1.28 μg/ml, respectively (p = 0.04).",Effects of Genetic Polymorphisms of Cytochrome P450 Enzymes and MDR1 Transporter on Pantoprazole Metabolism and Helicobacter pylori Eradication. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27611887/),[μg] / [ml],1.28,30716,DB00213,Pantoprazole
,28878983,limit of detection,"Under optimum conditions, the linear response of the peak with concentration of the cited drug was in the range of 6.6-360 × 10-8 M with limit of detection of 2.2 × 10-8 M.",Development of a novel and cost-effective redox sensor for voltammetric determination of pantoprazole sodium during pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28878983/),M,2.2 × 10-8,32520,DB00213,Pantoprazole
,21935988,AUC( 0-∞) ratio,"The AUC( 0-∞) ratio of (+)-/(-)-[(13) C]-pantoprazole was 3.45, 0.77, and 0.67 in PM, IM, and EM genotypes, respectively.",Stereoselective pharmacokinetics of stable isotope (+/-)-[13C]-pantoprazole: Implications for a rapid screening phenotype test of CYP2C19 activity. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21935988/),,3.45,34844,DB00213,Pantoprazole
,21935988,AUC( 0-∞) ratio,"The AUC( 0-∞) ratio of (+)-/(-)-[(13) C]-pantoprazole was 3.45, 0.77, and 0.67 in PM, IM, and EM genotypes, respectively.",Stereoselective pharmacokinetics of stable isotope (+/-)-[13C]-pantoprazole: Implications for a rapid screening phenotype test of CYP2C19 activity. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21935988/),,0.77,34845,DB00213,Pantoprazole
,21935988,AUC( 0-∞) ratio,"The AUC( 0-∞) ratio of (+)-/(-)-[(13) C]-pantoprazole was 3.45, 0.77, and 0.67 in PM, IM, and EM genotypes, respectively.",Stereoselective pharmacokinetics of stable isotope (+/-)-[13C]-pantoprazole: Implications for a rapid screening phenotype test of CYP2C19 activity. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21935988/),,0.67,34846,DB00213,Pantoprazole
,34262326,area under the curve (AUC; 0-T,"The area under the curve (AUC; 0-T, 300.342 ± 35.832 mg/L* h; AUC 0-∞, 320.462 ± 40.213 mg/L* h), the plasma peak concentration (30.622 ± 9.917 mg/L*), and the peak time and half-life (7.954 ± 1.121 h) in the clopidogrel and the TCM groups were higher than those in the clopidogrel and pantoprazole groups.",Study on the Effect of Antiplatelet and Gastric Mucosal Protection of Traditional Chinese Medicine Invigorating Qi and Hemostasis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34262326/),[mg] / [h·l],300.342,35155,DB00213,Pantoprazole
,34262326,AUC 0-∞,"The area under the curve (AUC; 0-T, 300.342 ± 35.832 mg/L* h; AUC 0-∞, 320.462 ± 40.213 mg/L* h), the plasma peak concentration (30.622 ± 9.917 mg/L*), and the peak time and half-life (7.954 ± 1.121 h) in the clopidogrel and the TCM groups were higher than those in the clopidogrel and pantoprazole groups.",Study on the Effect of Antiplatelet and Gastric Mucosal Protection of Traditional Chinese Medicine Invigorating Qi and Hemostasis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34262326/),[mg] / [h·l],320.462,35156,DB00213,Pantoprazole
,34262326,plasma peak concentration,"The area under the curve (AUC; 0-T, 300.342 ± 35.832 mg/L* h; AUC 0-∞, 320.462 ± 40.213 mg/L* h), the plasma peak concentration (30.622 ± 9.917 mg/L*), and the peak time and half-life (7.954 ± 1.121 h) in the clopidogrel and the TCM groups were higher than those in the clopidogrel and pantoprazole groups.",Study on the Effect of Antiplatelet and Gastric Mucosal Protection of Traditional Chinese Medicine Invigorating Qi and Hemostasis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34262326/),[mg] / [l],30.622,35157,DB00213,Pantoprazole
,34262326,peak time,"The area under the curve (AUC; 0-T, 300.342 ± 35.832 mg/L* h; AUC 0-∞, 320.462 ± 40.213 mg/L* h), the plasma peak concentration (30.622 ± 9.917 mg/L*), and the peak time and half-life (7.954 ± 1.121 h) in the clopidogrel and the TCM groups were higher than those in the clopidogrel and pantoprazole groups.",Study on the Effect of Antiplatelet and Gastric Mucosal Protection of Traditional Chinese Medicine Invigorating Qi and Hemostasis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34262326/),h,7.954,35158,DB00213,Pantoprazole
,34262326,half-life,"The area under the curve (AUC; 0-T, 300.342 ± 35.832 mg/L* h; AUC 0-∞, 320.462 ± 40.213 mg/L* h), the plasma peak concentration (30.622 ± 9.917 mg/L*), and the peak time and half-life (7.954 ± 1.121 h) in the clopidogrel and the TCM groups were higher than those in the clopidogrel and pantoprazole groups.",Study on the Effect of Antiplatelet and Gastric Mucosal Protection of Traditional Chinese Medicine Invigorating Qi and Hemostasis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34262326/),h,7.954,35159,DB00213,Pantoprazole
,22286158,apparent clearance,"A one-compartment model with first order absorption and elimination as the basic structural model appropriately described the data, with an apparent clearance of 56.8 L/h [95% confidence interval (CI) 52.8–60.8 L/h] and an apparent volume of distribution of 2,130 L (95% CI 1,646–2,614 L).",Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22286158/),[l] / [h],56.8,37925,DB00213,Pantoprazole
,22286158,apparent volume of distribution,"A one-compartment model with first order absorption and elimination as the basic structural model appropriately described the data, with an apparent clearance of 56.8 L/h [95% confidence interval (CI) 52.8–60.8 L/h] and an apparent volume of distribution of 2,130 L (95% CI 1,646–2,614 L).",Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22286158/),l,"2,130",37926,DB00213,Pantoprazole
,28238945,brain/plasma ratio,"Following intravenous administration, the brain/plasma ratio for imatinib was calculated to be 2% and remained at this ratio for 30min.",Nose-to-brain transport of imatinib mesylate: A pharmacokinetic evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28238945/),%,2,40263,DB00213,Pantoprazole
,28238945,brain/plasma ratio,"The brain/plasma ratio following intranasal administration, however, was found to be 5.3% and remained at this ratio for up to 90min.",Nose-to-brain transport of imatinib mesylate: A pharmacokinetic evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28238945/),%,5.3,40264,DB00213,Pantoprazole
,8405016,total plasma clearance,The plasma pharmacokinetics of pantoprazole following intravenous infusion in this group of subjects were characterised by a total plasma clearance of 0.13 l.h-1 x kg-1 and apparent terminal elimination half-life 1.9 h.,Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8405016/),[l] / [h·kg],0.13,41440,DB00213,Pantoprazole
,8405016,apparent terminal elimination half-life,The plasma pharmacokinetics of pantoprazole following intravenous infusion in this group of subjects were characterised by a total plasma clearance of 0.13 l.h-1 x kg-1 and apparent terminal elimination half-life 1.9 h.,Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8405016/),h,1.9,41441,DB00213,Pantoprazole
,8405016,apparent volume of distribution,The apparent volume of distribution estimated at steady state (0.17 l.kg-1) was compatible with the localization of a major fraction of the compound in extracellular water.,Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8405016/),[l] / [kg],0.17,41442,DB00213,Pantoprazole
,8405016,absolute systemic bioavailability,"Pantoprazole was well absorbed following oral administration; the absolute systemic bioavailability of the compound was estimated as 77% (95% CI, 67 to 89%).",Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8405016/),%,77,41443,DB00213,Pantoprazole
,8864328,clearance,"There was no effect on diazepam clearance (0.021 1 h-1 kg-1 for test and reference) and elimination half-life (36.8 for test, 40.4 h for reference).",Lack of pharmacokinetic interaction of pantoprazole with diazepam in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864328/),[1] / [h·kg],0.021,44920,DB00213,Pantoprazole
,8864328,elimination half-life,"There was no effect on diazepam clearance (0.021 1 h-1 kg-1 for test and reference) and elimination half-life (36.8 for test, 40.4 h for reference).",Lack of pharmacokinetic interaction of pantoprazole with diazepam in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864328/),h,36.8,44921,DB00213,Pantoprazole
,8864328,elimination half-life,"There was no effect on diazepam clearance (0.021 1 h-1 kg-1 for test and reference) and elimination half-life (36.8 for test, 40.4 h for reference).",Lack of pharmacokinetic interaction of pantoprazole with diazepam in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864328/),h,40.4,44922,DB00213,Pantoprazole
,20434410,m/,"PS and PSD3 were detected with proton adducts at m/z 384.2-->200.1 and 387.1-->203.1 in multiple reaction monitoring (MRM) positive mode, respectively.",Development and validation of a sensitive bioanalytical method for the quantitative estimation of pantoprazole in human plasma samples by LC-MS/MS: application to bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20434410/),,384.2,50172,DB00213,Pantoprazole
,20434410,m/,"PS and PSD3 were detected with proton adducts at m/z 384.2-->200.1 and 387.1-->203.1 in multiple reaction monitoring (MRM) positive mode, respectively.",Development and validation of a sensitive bioanalytical method for the quantitative estimation of pantoprazole in human plasma samples by LC-MS/MS: application to bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20434410/),,200.1,50173,DB00213,Pantoprazole
,20434410,m/,"PS and PSD3 were detected with proton adducts at m/z 384.2-->200.1 and 387.1-->203.1 in multiple reaction monitoring (MRM) positive mode, respectively.",Development and validation of a sensitive bioanalytical method for the quantitative estimation of pantoprazole in human plasma samples by LC-MS/MS: application to bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20434410/),,387.1,50174,DB00213,Pantoprazole
,20434410,m/,"PS and PSD3 were detected with proton adducts at m/z 384.2-->200.1 and 387.1-->203.1 in multiple reaction monitoring (MRM) positive mode, respectively.",Development and validation of a sensitive bioanalytical method for the quantitative estimation of pantoprazole in human plasma samples by LC-MS/MS: application to bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20434410/),,203.1,50175,DB00213,Pantoprazole
,30216801,VRC,"Interestingly, patients in the PPIs groups were more likely to reach the therapeutic VRC range of 1-5.5 μg/mL in steady state when compared with control patients (75-81% VS 69%).",The impact of proton pump inhibitors on the pharmacokinetics of voriconazole in vitro and in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30216801/),[μg] / [ml],1-5.5,56720,DB00213,Pantoprazole
,20384953,Third compartment pH,"Third compartment pH increased from 1.73+/-0.6 at baseline to 3.05+/-1.1, 4.02+/-1.4, and 3.61+/-1.6 at 24, 48, and 72 hours after SC administration, respectively.",Efficacy and pharmacokinetics of pantoprazole in alpacas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20384953/),,1.73,57167,DB00213,Pantoprazole
,20384953,Third compartment pH,"Third compartment pH increased from 1.73+/-0.6 at baseline to 3.05+/-1.1, 4.02+/-1.4, and 3.61+/-1.6 at 24, 48, and 72 hours after SC administration, respectively.",Efficacy and pharmacokinetics of pantoprazole in alpacas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20384953/),,3.05,57168,DB00213,Pantoprazole
,20384953,Third compartment pH,"Third compartment pH increased from 1.73+/-0.6 at baseline to 3.05+/-1.1, 4.02+/-1.4, and 3.61+/-1.6 at 24, 48, and 72 hours after SC administration, respectively.",Efficacy and pharmacokinetics of pantoprazole in alpacas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20384953/),,4.02,57169,DB00213,Pantoprazole
,20384953,Third compartment pH,"Third compartment pH increased from 1.73+/-0.6 at baseline to 3.05+/-1.1, 4.02+/-1.4, and 3.61+/-1.6 at 24, 48, and 72 hours after SC administration, respectively.",Efficacy and pharmacokinetics of pantoprazole in alpacas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20384953/),,3.61,57170,DB00213,Pantoprazole
,20384953,elimination half-life,Pharmacokinetic analysis demonstrated that pantoprazole had a short elimination half-life (0.47+0.06 h) and a high clearance rate (12.2+/-2.9 mL/kg/min) after both IV and SC administration.,Efficacy and pharmacokinetics of pantoprazole in alpacas. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20384953/),h,0.47,57171,DB00213,Pantoprazole
,20384953,clearance rate,Pharmacokinetic analysis demonstrated that pantoprazole had a short elimination half-life (0.47+0.06 h) and a high clearance rate (12.2+/-2.9 mL/kg/min) after both IV and SC administration.,Efficacy and pharmacokinetics of pantoprazole in alpacas. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20384953/),[ml] / [kg·min],12.2,57172,DB00213,Pantoprazole
,21740077,maximum (peak) plasma concentration,"Mean (standard deviation) maximum (peak) plasma concentration values for the low and high doses were 503 (506) ng/mL and 1318 (1307) ng/mL, respectively, in study 1, and 229 (196) ng/mL and 653 (645) ng/mL, respectively, in study 2.","Randomized, open-label, multicentre pharmacokinetic studies of two dose levels of pantoprazole granules in infants and children aged 1 month through <6 years with gastro-oesophageal reflux disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21740077/),[ng] / [ml],503,59458,DB00213,Pantoprazole
,21740077,maximum (peak) plasma concentration,"Mean (standard deviation) maximum (peak) plasma concentration values for the low and high doses were 503 (506) ng/mL and 1318 (1307) ng/mL, respectively, in study 1, and 229 (196) ng/mL and 653 (645) ng/mL, respectively, in study 2.","Randomized, open-label, multicentre pharmacokinetic studies of two dose levels of pantoprazole granules in infants and children aged 1 month through <6 years with gastro-oesophageal reflux disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21740077/),[ng] / [ml],1318,59459,DB00213,Pantoprazole
,21740077,maximum (peak) plasma concentration,"Mean (standard deviation) maximum (peak) plasma concentration values for the low and high doses were 503 (506) ng/mL and 1318 (1307) ng/mL, respectively, in study 1, and 229 (196) ng/mL and 653 (645) ng/mL, respectively, in study 2.","Randomized, open-label, multicentre pharmacokinetic studies of two dose levels of pantoprazole granules in infants and children aged 1 month through <6 years with gastro-oesophageal reflux disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21740077/),[ng] / [ml],229,59460,DB00213,Pantoprazole
,21740077,maximum (peak) plasma concentration,"Mean (standard deviation) maximum (peak) plasma concentration values for the low and high doses were 503 (506) ng/mL and 1318 (1307) ng/mL, respectively, in study 1, and 229 (196) ng/mL and 653 (645) ng/mL, respectively, in study 2.","Randomized, open-label, multicentre pharmacokinetic studies of two dose levels of pantoprazole granules in infants and children aged 1 month through <6 years with gastro-oesophageal reflux disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21740077/),[ng] / [ml],653,59461,DB00213,Pantoprazole
,21740077,Area under the plasma concentration-time curve,"Area under the plasma concentration-time curve values for the low and high doses were 1046 (1043) ng · h/mL and 3602 (3269) ng · h/mL, respectively, in study 1, and 293 (146) ng · h/mL and 2448 (2170) ng · h/mL, respectively, in study 2.","Randomized, open-label, multicentre pharmacokinetic studies of two dose levels of pantoprazole granules in infants and children aged 1 month through <6 years with gastro-oesophageal reflux disease. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21740077/),[h·ng] / [ml],1046,59462,DB00213,Pantoprazole
,21740077,Area under the plasma concentration-time curve,"Area under the plasma concentration-time curve values for the low and high doses were 1046 (1043) ng · h/mL and 3602 (3269) ng · h/mL, respectively, in study 1, and 293 (146) ng · h/mL and 2448 (2170) ng · h/mL, respectively, in study 2.","Randomized, open-label, multicentre pharmacokinetic studies of two dose levels of pantoprazole granules in infants and children aged 1 month through <6 years with gastro-oesophageal reflux disease. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21740077/),[h·ng] / [ml],3602,59463,DB00213,Pantoprazole
,21740077,Area under the plasma concentration-time curve,"Area under the plasma concentration-time curve values for the low and high doses were 1046 (1043) ng · h/mL and 3602 (3269) ng · h/mL, respectively, in study 1, and 293 (146) ng · h/mL and 2448 (2170) ng · h/mL, respectively, in study 2.","Randomized, open-label, multicentre pharmacokinetic studies of two dose levels of pantoprazole granules in infants and children aged 1 month through <6 years with gastro-oesophageal reflux disease. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21740077/),[h·ng] / [ml],293,59464,DB00213,Pantoprazole
,21740077,Area under the plasma concentration-time curve,"Area under the plasma concentration-time curve values for the low and high doses were 1046 (1043) ng · h/mL and 3602 (3269) ng · h/mL, respectively, in study 1, and 293 (146) ng · h/mL and 2448 (2170) ng · h/mL, respectively, in study 2.","Randomized, open-label, multicentre pharmacokinetic studies of two dose levels of pantoprazole granules in infants and children aged 1 month through <6 years with gastro-oesophageal reflux disease. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21740077/),[h·ng] / [ml],2448,59465,DB00213,Pantoprazole
,19481022,serum concentrations (C(0)),"In the PPI group, the mean daily MMF dose was 1,912 +/- 1,023 mg with mean pre-dose serum concentrations (C(0)) of 1.9 +/- 1.4 mg/liter, without a significant difference from controls.",Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19481022/),[mg] / [l],1.9,60240,DB00213,Pantoprazole
,19481022,concentrations at 30 minutes (C(0.5h),"Mean post-dose MPA concentrations at 30 minutes (C(0.5h)) were significantly higher in the control group (control, 17.9 +/- 11.5 mg/liter; PPI, 6.7 +/- 4.6 mg/liter; p < 0.001).",Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19481022/),[mg] / [l],17.9,60241,DB00213,Pantoprazole
,19481022,concentrations at 30 minutes (C(0.5h),"Mean post-dose MPA concentrations at 30 minutes (C(0.5h)) were significantly higher in the control group (control, 17.9 +/- 11.5 mg/liter; PPI, 6.7 +/- 4.6 mg/liter; p < 0.001).",Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19481022/),[mg] / [l],6.7,60242,DB00213,Pantoprazole
,19481022,"C(1h, 2h)","One- and 2-hour (C(1h, 2h)) MPA concentrations were persistently higher in the control group (1 hour: control, 13.8 +/- 9.1 mg/liter; PPI, 7.7 +/- 4.1 mg/liter; 2 hours: control, 7.6 +/- 4.2; PPI, 5.0 +/- 2.8 mg/liter; p < 0.05).",Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19481022/),[mg] / [l],13.8,60243,DB00213,Pantoprazole
,19481022,"C(1h, 2h)","One- and 2-hour (C(1h, 2h)) MPA concentrations were persistently higher in the control group (1 hour: control, 13.8 +/- 9.1 mg/liter; PPI, 7.7 +/- 4.1 mg/liter; 2 hours: control, 7.6 +/- 4.2; PPI, 5.0 +/- 2.8 mg/liter; p < 0.05).",Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19481022/),[mg] / [l],7.7,60244,DB00213,Pantoprazole
,19481022,"C(1h, 2h)","One- and 2-hour (C(1h, 2h)) MPA concentrations were persistently higher in the control group (1 hour: control, 13.8 +/- 9.1 mg/liter; PPI, 7.7 +/- 4.1 mg/liter; 2 hours: control, 7.6 +/- 4.2; PPI, 5.0 +/- 2.8 mg/liter; p < 0.05).",Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19481022/),[mg] / [l],7.6,60245,DB00213,Pantoprazole
,19481022,"C(1h, 2h)","One- and 2-hour (C(1h, 2h)) MPA concentrations were persistently higher in the control group (1 hour: control, 13.8 +/- 9.1 mg/liter; PPI, 7.7 +/- 4.1 mg/liter; 2 hours: control, 7.6 +/- 4.2; PPI, 5.0 +/- 2.8 mg/liter; p < 0.05).",Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19481022/),[mg] / [l],5.0,60246,DB00213,Pantoprazole
,19481022,C(12h),"In the subgroup with full AUC measurements, the control group had higher MPA levels 12 hours after dosing (C(12h): control, 3.3 +/- 2.4 mg/liter; PPI, 1.6 +/- 1.3 mg/liter; p < 0.05) and a significantly higher dose-adjusted AUC C(0-3h) (control, 59.5 +/- 20.7 mg/liter; PPI, 41.7 +/- 23.4 mg/liter; p < 0.05).",Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19481022/),[mg] / [l],3.3,60247,DB00213,Pantoprazole
,19481022,C(12h),"In the subgroup with full AUC measurements, the control group had higher MPA levels 12 hours after dosing (C(12h): control, 3.3 +/- 2.4 mg/liter; PPI, 1.6 +/- 1.3 mg/liter; p < 0.05) and a significantly higher dose-adjusted AUC C(0-3h) (control, 59.5 +/- 20.7 mg/liter; PPI, 41.7 +/- 23.4 mg/liter; p < 0.05).",Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19481022/),[mg] / [l],1.6,60248,DB00213,Pantoprazole
,19481022,AUC C(0-3h),"In the subgroup with full AUC measurements, the control group had higher MPA levels 12 hours after dosing (C(12h): control, 3.3 +/- 2.4 mg/liter; PPI, 1.6 +/- 1.3 mg/liter; p < 0.05) and a significantly higher dose-adjusted AUC C(0-3h) (control, 59.5 +/- 20.7 mg/liter; PPI, 41.7 +/- 23.4 mg/liter; p < 0.05).",Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19481022/),[mg] / [l],59.5,60249,DB00213,Pantoprazole
,19481022,AUC C(0-3h),"In the subgroup with full AUC measurements, the control group had higher MPA levels 12 hours after dosing (C(12h): control, 3.3 +/- 2.4 mg/liter; PPI, 1.6 +/- 1.3 mg/liter; p < 0.05) and a significantly higher dose-adjusted AUC C(0-3h) (control, 59.5 +/- 20.7 mg/liter; PPI, 41.7 +/- 23.4 mg/liter; p < 0.05).",Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19481022/),[mg] / [l],41.7,60250,DB00213,Pantoprazole
,19481022,maximum plasma concentration of mycophenolic acid (,"In the subgroup, the maximum plasma concentration of mycophenolic acid (MPA C(max)) in the PPI group was significantly lower (10.1 +/- 4.7 mg/liter) than in the control group (45.5 +/- 53.5 mg/liter, p < 0.0001), whereas t(max) revealed no differences (control: 1.1 +/- 0.77 hours; PPI: 1.1 +/- 0.97 hours).",Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19481022/),[mg] / [l],10.1,60251,DB00213,Pantoprazole
,19481022,maximum plasma concentration of mycophenolic acid (,"In the subgroup, the maximum plasma concentration of mycophenolic acid (MPA C(max)) in the PPI group was significantly lower (10.1 +/- 4.7 mg/liter) than in the control group (45.5 +/- 53.5 mg/liter, p < 0.0001), whereas t(max) revealed no differences (control: 1.1 +/- 0.77 hours; PPI: 1.1 +/- 0.97 hours).",Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19481022/),[mg] / [l],45.5,60252,DB00213,Pantoprazole
,19481022,t(max),"In the subgroup, the maximum plasma concentration of mycophenolic acid (MPA C(max)) in the PPI group was significantly lower (10.1 +/- 4.7 mg/liter) than in the control group (45.5 +/- 53.5 mg/liter, p < 0.0001), whereas t(max) revealed no differences (control: 1.1 +/- 0.77 hours; PPI: 1.1 +/- 0.97 hours).",Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19481022/),h,1.1,60253,DB00213,Pantoprazole
,19481022,t(max),"In the subgroup, the maximum plasma concentration of mycophenolic acid (MPA C(max)) in the PPI group was significantly lower (10.1 +/- 4.7 mg/liter) than in the control group (45.5 +/- 53.5 mg/liter, p < 0.0001), whereas t(max) revealed no differences (control: 1.1 +/- 0.77 hours; PPI: 1.1 +/- 0.97 hours).",Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19481022/),h,1.1,60254,DB00213,Pantoprazole
,20484619,clearance (CL),"Data were described using a 2-compartment model with a typical parameterized in terms of clearance (CL) (95% CI) of 1.93 L per hour (1.53, 2.61), given the reference covariates (female, full term, extensive/unknown CYP2C19 metabolizer status, non-African American, 10 kg weight, intravenous or tablet administration).",Population pharmacokinetic modeling of pantoprazole in pediatric patients from birth to 16 years. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20484619/),[l] / [h],1.93,66597,DB00213,Pantoprazole
,27349958,run time,The separation of pantoprazole enantiomers was performed on a CHIRALCEL OJ-RH column and an overlapping injection mode was used to achieve a run time of 5.0 min/sample.,High-Throughput Chiral LC-MS/MS Method Using Overlapping Injection Mode for the Determination of Pantoprazole Enantiomers in Human Plasma with Application to Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27349958/),[min] / [sample],5.0,79677,DB00213,Pantoprazole
,27349958,flow rate,Isocratic elution was used with flow rate at 500 μL/min.,High-Throughput Chiral LC-MS/MS Method Using Overlapping Injection Mode for the Determination of Pantoprazole Enantiomers in Human Plasma with Application to Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27349958/),[μl] / [min],500,79678,DB00213,Pantoprazole
,27349958,m/z,The enantiomers were quantified on a triple-quadrupole mass spectrometer under multiple reaction monitoring (MRM) mode with m/z 382.1/230.0 for pantoprazole and m/z 388.4/230.1 for pantoprazole-d7.,High-Throughput Chiral LC-MS/MS Method Using Overlapping Injection Mode for the Determination of Pantoprazole Enantiomers in Human Plasma with Application to Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27349958/),,382.1,79679,DB00213,Pantoprazole
,27349958,m/z,The enantiomers were quantified on a triple-quadrupole mass spectrometer under multiple reaction monitoring (MRM) mode with m/z 382.1/230.0 for pantoprazole and m/z 388.4/230.1 for pantoprazole-d7.,High-Throughput Chiral LC-MS/MS Method Using Overlapping Injection Mode for the Determination of Pantoprazole Enantiomers in Human Plasma with Application to Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27349958/),,230.0,79680,DB00213,Pantoprazole
,27349958,m/z,The enantiomers were quantified on a triple-quadrupole mass spectrometer under multiple reaction monitoring (MRM) mode with m/z 382.1/230.0 for pantoprazole and m/z 388.4/230.1 for pantoprazole-d7.,High-Throughput Chiral LC-MS/MS Method Using Overlapping Injection Mode for the Determination of Pantoprazole Enantiomers in Human Plasma with Application to Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27349958/),,388.4,79681,DB00213,Pantoprazole
,27349958,m/z,The enantiomers were quantified on a triple-quadrupole mass spectrometer under multiple reaction monitoring (MRM) mode with m/z 382.1/230.0 for pantoprazole and m/z 388.4/230.1 for pantoprazole-d7.,High-Throughput Chiral LC-MS/MS Method Using Overlapping Injection Mode for the Determination of Pantoprazole Enantiomers in Human Plasma with Application to Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27349958/),,230.1,79682,DB00213,Pantoprazole
,27349958,Extraction recovery,"Extraction recovery ranged from 91.7% to 96.4% for R-pantoprazole and from 92.5% to 96.5% for S-pantoprazole and the IS-normalized matrix factor was 0.98 to 1.07 for R-pantoprazole and S-pantoprazole, respectively.",High-Throughput Chiral LC-MS/MS Method Using Overlapping Injection Mode for the Determination of Pantoprazole Enantiomers in Human Plasma with Application to Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27349958/),%,91.7,79683,DB00213,Pantoprazole
,27349958,Extraction recovery,"Extraction recovery ranged from 91.7% to 96.4% for R-pantoprazole and from 92.5% to 96.5% for S-pantoprazole and the IS-normalized matrix factor was 0.98 to 1.07 for R-pantoprazole and S-pantoprazole, respectively.",High-Throughput Chiral LC-MS/MS Method Using Overlapping Injection Mode for the Determination of Pantoprazole Enantiomers in Human Plasma with Application to Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27349958/),%,96.4,79684,DB00213,Pantoprazole
,27349958,Extraction recovery,"Extraction recovery ranged from 91.7% to 96.4% for R-pantoprazole and from 92.5% to 96.5% for S-pantoprazole and the IS-normalized matrix factor was 0.98 to 1.07 for R-pantoprazole and S-pantoprazole, respectively.",High-Throughput Chiral LC-MS/MS Method Using Overlapping Injection Mode for the Determination of Pantoprazole Enantiomers in Human Plasma with Application to Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27349958/),%,92.5,79685,DB00213,Pantoprazole
,27349958,Extraction recovery,"Extraction recovery ranged from 91.7% to 96.4% for R-pantoprazole and from 92.5% to 96.5% for S-pantoprazole and the IS-normalized matrix factor was 0.98 to 1.07 for R-pantoprazole and S-pantoprazole, respectively.",High-Throughput Chiral LC-MS/MS Method Using Overlapping Injection Mode for the Determination of Pantoprazole Enantiomers in Human Plasma with Application to Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27349958/),%,96.5,79686,DB00213,Pantoprazole
,15975247,flow rate,"Following a protein precipitation procedure, the samples are separated using reversed-phase HPLC (C18) by a gradient of acetonitrile and ammonium acetate (pH 6.0) at a flow rate of 1.0 mL/min and quantitated using UV detection at 290 nm.",Simultaneous determination of pantoprazole and its two metabolites in dog plasma by HPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15975247/),[ml] / [min],1.0,81301,DB00213,Pantoprazole
,25213162,maximum serum concentration,Median maximum serum concentration of pantoprazole was 84.3 μM at 1-2 h after injection of pantoprazole 240 mg.,A phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25213162/),μM,84.3,82784,DB00213,Pantoprazole
,19569219,plasma AUC((0-infinity)),"Geometric mean (95% CI) sulfasalazine plasma AUC((0-infinity)) values were 32.1 (13.2, 78.1), 16.8 (7.15, 39.6) and 62.7 (33.4, 118) microg h/mL, and C(max) were 4.01 (1.62, 9.92), 1.70 (0.66, 4.40), and 6.86 (3.61, 13.0) microg/mL for CC, CA, and AA subjects, respectively.",Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19569219/),[h·μg] / [ml],32.1,89963,DB00213,Pantoprazole
,19569219,plasma AUC((0-infinity)),"Geometric mean (95% CI) sulfasalazine plasma AUC((0-infinity)) values were 32.1 (13.2, 78.1), 16.8 (7.15, 39.6) and 62.7 (33.4, 118) microg h/mL, and C(max) were 4.01 (1.62, 9.92), 1.70 (0.66, 4.40), and 6.86 (3.61, 13.0) microg/mL for CC, CA, and AA subjects, respectively.",Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19569219/),[h·μg] / [ml],16.8,89964,DB00213,Pantoprazole
,19569219,plasma AUC((0-infinity)),"Geometric mean (95% CI) sulfasalazine plasma AUC((0-infinity)) values were 32.1 (13.2, 78.1), 16.8 (7.15, 39.6) and 62.7 (33.4, 118) microg h/mL, and C(max) were 4.01 (1.62, 9.92), 1.70 (0.66, 4.40), and 6.86 (3.61, 13.0) microg/mL for CC, CA, and AA subjects, respectively.",Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19569219/),[h·μg] / [ml],62.7,89965,DB00213,Pantoprazole
,19569219,C(max),"Geometric mean (95% CI) sulfasalazine plasma AUC((0-infinity)) values were 32.1 (13.2, 78.1), 16.8 (7.15, 39.6) and 62.7 (33.4, 118) microg h/mL, and C(max) were 4.01 (1.62, 9.92), 1.70 (0.66, 4.40), and 6.86 (3.61, 13.0) microg/mL for CC, CA, and AA subjects, respectively.",Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19569219/),[μg] / [ml],4.01,89966,DB00213,Pantoprazole
,19569219,C(max),"Geometric mean (95% CI) sulfasalazine plasma AUC((0-infinity)) values were 32.1 (13.2, 78.1), 16.8 (7.15, 39.6) and 62.7 (33.4, 118) microg h/mL, and C(max) were 4.01 (1.62, 9.92), 1.70 (0.66, 4.40), and 6.86 (3.61, 13.0) microg/mL for CC, CA, and AA subjects, respectively.",Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19569219/),[μg] / [ml],1.70,89967,DB00213,Pantoprazole
,19569219,C(max),"Geometric mean (95% CI) sulfasalazine plasma AUC((0-infinity)) values were 32.1 (13.2, 78.1), 16.8 (7.15, 39.6) and 62.7 (33.4, 118) microg h/mL, and C(max) were 4.01 (1.62, 9.92), 1.70 (0.66, 4.40), and 6.86 (3.61, 13.0) microg/mL for CC, CA, and AA subjects, respectively.",Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19569219/),[μg] / [ml],6.86,89968,DB00213,Pantoprazole
,17080510,retention times,"The retention times for tenatoprazole and internal standard were 7.1 and 12.3 min, respectively.",HPLC determination and pharmacokinetic study of tenatoprazole in dog plasma after oral administration of enteric-coated capsule. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17080510/),min,7.1,90415,DB00213,Pantoprazole
,17080510,retention times,"The retention times for tenatoprazole and internal standard were 7.1 and 12.3 min, respectively.",HPLC determination and pharmacokinetic study of tenatoprazole in dog plasma after oral administration of enteric-coated capsule. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17080510/),min,12.3,90416,DB00213,Pantoprazole
,17080510,C(max),The plasma concentration of tenatoprazole from six dogs showed a mean C(max) of 2.63 microg/mL at T(max) of 1.89 h.,HPLC determination and pharmacokinetic study of tenatoprazole in dog plasma after oral administration of enteric-coated capsule. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17080510/),[μg] / [ml],2.63,90417,DB00213,Pantoprazole
,17080510,T(max),The plasma concentration of tenatoprazole from six dogs showed a mean C(max) of 2.63 microg/mL at T(max) of 1.89 h.,HPLC determination and pharmacokinetic study of tenatoprazole in dog plasma after oral administration of enteric-coated capsule. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17080510/),h,1.89,90418,DB00213,Pantoprazole
,8897077,maximum concentration in serum (Cmax),The mean maximum concentration in serum (Cmax) ranged from 1.77-9.25 micrograms/ml for the 20-120 mg dose and the mean time to reach Cmax (tmax) ranged from 1.92-2.42 h.,"Pharmacokinetics and tolerance of pantoprazole, a proton pump inhibitor after single and multiple oral doses in healthy Japanese volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8897077/),[μg] / [ml],1.77-9.25,94601,DB00213,Pantoprazole
,8897077,time to reach Cmax (tmax),The mean maximum concentration in serum (Cmax) ranged from 1.77-9.25 micrograms/ml for the 20-120 mg dose and the mean time to reach Cmax (tmax) ranged from 1.92-2.42 h.,"Pharmacokinetics and tolerance of pantoprazole, a proton pump inhibitor after single and multiple oral doses in healthy Japanese volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8897077/),h,1.92-2.42,94602,DB00213,Pantoprazole
,8897077,half-life (t1/2),The half-life (t1/2) ranged from 0.74-1.16 h.,"Pharmacokinetics and tolerance of pantoprazole, a proton pump inhibitor after single and multiple oral doses in healthy Japanese volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8897077/),h,0.74-1.16,94603,DB00213,Pantoprazole
,10442511,MIC,"In all tissue samples, azithromycin concentrations were well above the MIC for H. pylori (0.25 microg/ml).",Determination of azithromycin in gastric biopsy samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10442511/),[μg] / [ml],0.25,103484,DB00213,Pantoprazole
,2177296,percent inhibition,"Repeated once-daily infusion (15 min) of pantoprazole resulted in a rapidly increasing pharmacodynamic effect: as compared to placebo the mean percent inhibition of acid output measured from 1 to 3 h after start of infusion was 22%, 63% and 78% for the 15 mg dose, and 56%, 97% and 99% for the 30 mg dose on days 1, 4 and 5, respectively.","Pentagastrin-stimulated gastric acid secretion and pharmacokinetics following single and repeated intravenous administration of the gastric H+, K(+)-ATPase-inhibitor pantoprazole (BY1023/SK&F96022) in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2177296/),%,22,111807,DB00213,Pantoprazole
,2177296,percent inhibition,"Repeated once-daily infusion (15 min) of pantoprazole resulted in a rapidly increasing pharmacodynamic effect: as compared to placebo the mean percent inhibition of acid output measured from 1 to 3 h after start of infusion was 22%, 63% and 78% for the 15 mg dose, and 56%, 97% and 99% for the 30 mg dose on days 1, 4 and 5, respectively.","Pentagastrin-stimulated gastric acid secretion and pharmacokinetics following single and repeated intravenous administration of the gastric H+, K(+)-ATPase-inhibitor pantoprazole (BY1023/SK&F96022) in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2177296/),%,63,111808,DB00213,Pantoprazole
,2177296,percent inhibition,"Repeated once-daily infusion (15 min) of pantoprazole resulted in a rapidly increasing pharmacodynamic effect: as compared to placebo the mean percent inhibition of acid output measured from 1 to 3 h after start of infusion was 22%, 63% and 78% for the 15 mg dose, and 56%, 97% and 99% for the 30 mg dose on days 1, 4 and 5, respectively.","Pentagastrin-stimulated gastric acid secretion and pharmacokinetics following single and repeated intravenous administration of the gastric H+, K(+)-ATPase-inhibitor pantoprazole (BY1023/SK&F96022) in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2177296/),%,78,111809,DB00213,Pantoprazole
,2177296,percent inhibition,"Repeated once-daily infusion (15 min) of pantoprazole resulted in a rapidly increasing pharmacodynamic effect: as compared to placebo the mean percent inhibition of acid output measured from 1 to 3 h after start of infusion was 22%, 63% and 78% for the 15 mg dose, and 56%, 97% and 99% for the 30 mg dose on days 1, 4 and 5, respectively.","Pentagastrin-stimulated gastric acid secretion and pharmacokinetics following single and repeated intravenous administration of the gastric H+, K(+)-ATPase-inhibitor pantoprazole (BY1023/SK&F96022) in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2177296/),%,56,111810,DB00213,Pantoprazole
,2177296,percent inhibition,"Repeated once-daily infusion (15 min) of pantoprazole resulted in a rapidly increasing pharmacodynamic effect: as compared to placebo the mean percent inhibition of acid output measured from 1 to 3 h after start of infusion was 22%, 63% and 78% for the 15 mg dose, and 56%, 97% and 99% for the 30 mg dose on days 1, 4 and 5, respectively.","Pentagastrin-stimulated gastric acid secretion and pharmacokinetics following single and repeated intravenous administration of the gastric H+, K(+)-ATPase-inhibitor pantoprazole (BY1023/SK&F96022) in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2177296/),%,97,111811,DB00213,Pantoprazole
,2177296,percent inhibition,"Repeated once-daily infusion (15 min) of pantoprazole resulted in a rapidly increasing pharmacodynamic effect: as compared to placebo the mean percent inhibition of acid output measured from 1 to 3 h after start of infusion was 22%, 63% and 78% for the 15 mg dose, and 56%, 97% and 99% for the 30 mg dose on days 1, 4 and 5, respectively.","Pentagastrin-stimulated gastric acid secretion and pharmacokinetics following single and repeated intravenous administration of the gastric H+, K(+)-ATPase-inhibitor pantoprazole (BY1023/SK&F96022) in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2177296/),%,99,111812,DB00213,Pantoprazole
,9623552,AUC,"The pharmacokinetic characteristics of pantoprazole AUC, t(1/2), CL and V(d area) (geometric means) were 2.4 mgxh/l, 0.63 h, 0.227 l/h/kg and 0.206 l/kg on day A (without dialysis) and 2.3 mgxh/l, 0.8 h, 0.237 l/h/kg and 0.273 l/kg on day B (with dialysis), respectively.",Pharmacokinetics of pantoprazole in patients with end-stage renal failure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9623552/),[h·mg] / [l],2.4,115284,DB00213,Pantoprazole
,9623552,t(1/2),"The pharmacokinetic characteristics of pantoprazole AUC, t(1/2), CL and V(d area) (geometric means) were 2.4 mgxh/l, 0.63 h, 0.227 l/h/kg and 0.206 l/kg on day A (without dialysis) and 2.3 mgxh/l, 0.8 h, 0.237 l/h/kg and 0.273 l/kg on day B (with dialysis), respectively.",Pharmacokinetics of pantoprazole in patients with end-stage renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9623552/),h,0.63,115285,DB00213,Pantoprazole
,9623552,t(1/2),"The pharmacokinetic characteristics of pantoprazole AUC, t(1/2), CL and V(d area) (geometric means) were 2.4 mgxh/l, 0.63 h, 0.227 l/h/kg and 0.206 l/kg on day A (without dialysis) and 2.3 mgxh/l, 0.8 h, 0.237 l/h/kg and 0.273 l/kg on day B (with dialysis), respectively.",Pharmacokinetics of pantoprazole in patients with end-stage renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9623552/),[l] / [h·kg],0.237,115286,DB00213,Pantoprazole
,9623552,CL,"The pharmacokinetic characteristics of pantoprazole AUC, t(1/2), CL and V(d area) (geometric means) were 2.4 mgxh/l, 0.63 h, 0.227 l/h/kg and 0.206 l/kg on day A (without dialysis) and 2.3 mgxh/l, 0.8 h, 0.237 l/h/kg and 0.273 l/kg on day B (with dialysis), respectively.",Pharmacokinetics of pantoprazole in patients with end-stage renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9623552/),h,0.63,115287,DB00213,Pantoprazole
,9623552,CL,"The pharmacokinetic characteristics of pantoprazole AUC, t(1/2), CL and V(d area) (geometric means) were 2.4 mgxh/l, 0.63 h, 0.227 l/h/kg and 0.206 l/kg on day A (without dialysis) and 2.3 mgxh/l, 0.8 h, 0.237 l/h/kg and 0.273 l/kg on day B (with dialysis), respectively.",Pharmacokinetics of pantoprazole in patients with end-stage renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9623552/),[l] / [h·kg],0.227,115288,DB00213,Pantoprazole
,9623552,CL,"The pharmacokinetic characteristics of pantoprazole AUC, t(1/2), CL and V(d area) (geometric means) were 2.4 mgxh/l, 0.63 h, 0.227 l/h/kg and 0.206 l/kg on day A (without dialysis) and 2.3 mgxh/l, 0.8 h, 0.237 l/h/kg and 0.273 l/kg on day B (with dialysis), respectively.",Pharmacokinetics of pantoprazole in patients with end-stage renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9623552/),h,0.8,115289,DB00213,Pantoprazole
,9623552,CL,"The pharmacokinetic characteristics of pantoprazole AUC, t(1/2), CL and V(d area) (geometric means) were 2.4 mgxh/l, 0.63 h, 0.227 l/h/kg and 0.206 l/kg on day A (without dialysis) and 2.3 mgxh/l, 0.8 h, 0.237 l/h/kg and 0.273 l/kg on day B (with dialysis), respectively.",Pharmacokinetics of pantoprazole in patients with end-stage renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9623552/),[l] / [h·kg],0.237,115290,DB00213,Pantoprazole
,9623552,V(d area),"The pharmacokinetic characteristics of pantoprazole AUC, t(1/2), CL and V(d area) (geometric means) were 2.4 mgxh/l, 0.63 h, 0.227 l/h/kg and 0.206 l/kg on day A (without dialysis) and 2.3 mgxh/l, 0.8 h, 0.237 l/h/kg and 0.273 l/kg on day B (with dialysis), respectively.",Pharmacokinetics of pantoprazole in patients with end-stage renal failure. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9623552/),[l] / [kg],0.206,115291,DB00213,Pantoprazole
,9623552,V(d area),"The pharmacokinetic characteristics of pantoprazole AUC, t(1/2), CL and V(d area) (geometric means) were 2.4 mgxh/l, 0.63 h, 0.227 l/h/kg and 0.206 l/kg on day A (without dialysis) and 2.3 mgxh/l, 0.8 h, 0.237 l/h/kg and 0.273 l/kg on day B (with dialysis), respectively.",Pharmacokinetics of pantoprazole in patients with end-stage renal failure. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9623552/),[l] / [kg],0.273,115292,DB00213,Pantoprazole
,9623552,protein binding,The protein binding was 96%.,Pharmacokinetics of pantoprazole in patients with end-stage renal failure. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9623552/),%,96,115293,DB00213,Pantoprazole
,11421879,cure rates,"The cure rates of H. pylori infection in the PAC 250 and PAC 500 groups were, respectively, 83% and 79% (ITT analysis) and 94% and 88% (PP analysis) (P=N.S.).",Cure of Helicobacter pylori infection in elderly patients: comparison of low versus high doses of clarithromycin in combination with amoxicillin and pantoprazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11421879/),%,83,118973,DB00213,Pantoprazole
,11421879,cure rates,"The cure rates of H. pylori infection in the PAC 250 and PAC 500 groups were, respectively, 83% and 79% (ITT analysis) and 94% and 88% (PP analysis) (P=N.S.).",Cure of Helicobacter pylori infection in elderly patients: comparison of low versus high doses of clarithromycin in combination with amoxicillin and pantoprazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11421879/),%,79,118974,DB00213,Pantoprazole
,11421879,cure rates,"The cure rates of H. pylori infection in the PAC 250 and PAC 500 groups were, respectively, 83% and 79% (ITT analysis) and 94% and 88% (PP analysis) (P=N.S.).",Cure of Helicobacter pylori infection in elderly patients: comparison of low versus high doses of clarithromycin in combination with amoxicillin and pantoprazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11421879/),%,94,118975,DB00213,Pantoprazole
,11421879,cure rates,"The cure rates of H. pylori infection in the PAC 250 and PAC 500 groups were, respectively, 83% and 79% (ITT analysis) and 94% and 88% (PP analysis) (P=N.S.).",Cure of Helicobacter pylori infection in elderly patients: comparison of low versus high doses of clarithromycin in combination with amoxicillin and pantoprazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11421879/),%,88,118976,DB00213,Pantoprazole
,15568407,milk/plasma ratio,"A milk/plasma ratio of 0.022 was observed at tmax, 2 hours after dose administration.",Excretion of pantoprazole in human breast. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15568407/),,0.022,119837,DB00213,Pantoprazole
,15568407,maximum consumption,Infant exposure was measured as maximum concentration in milk multiplied by an estimated maximum consumption of 200 mL at this time.,Excretion of pantoprazole in human breast. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15568407/),ml,200,119838,DB00213,Pantoprazole
,8738854,absolute bioavailability,Its absolute bioavailability is 77% and does not change upon multiple dosing.,Pharmacokinetics of pantoprazole in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738854/),%,77,126641,DB00213,Pantoprazole
,8738854,Cmax,"Following a single oral dose of 40 mg, Cmax is approximately 2.5 mg/l, with a tmax of 2-3 h.",Pharmacokinetics of pantoprazole in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738854/),[mg] / [l],2.5,126642,DB00213,Pantoprazole
,8738854,tmax,"Following a single oral dose of 40 mg, Cmax is approximately 2.5 mg/l, with a tmax of 2-3 h.",Pharmacokinetics of pantoprazole in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738854/),h,2-3,126643,DB00213,Pantoprazole
,8738854,AUC(O,"The AUC(O,inf.) is approximately 5 mgxh/l.",Pharmacokinetics of pantoprazole in man. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738854/),[h·mg] / [l],5,126644,DB00213,Pantoprazole
,8738854,total serum clearance,"Pantoprazole is extensively metabolized in the liver, has a total serum clearance of 0.1 l/h/kg, a serum elimination halflife of about 1.1 h, and an apparent volume of distribution of 0.15 l/kg. 98% of pantoprazole is bound to serum proteins.",Pharmacokinetics of pantoprazole in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738854/),[l] / [h·kg],0.1,126645,DB00213,Pantoprazole
,8738854,serum elimination halflife,"Pantoprazole is extensively metabolized in the liver, has a total serum clearance of 0.1 l/h/kg, a serum elimination halflife of about 1.1 h, and an apparent volume of distribution of 0.15 l/kg. 98% of pantoprazole is bound to serum proteins.",Pharmacokinetics of pantoprazole in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738854/),h,1.1,126646,DB00213,Pantoprazole
,8738854,apparent volume of distribution,"Pantoprazole is extensively metabolized in the liver, has a total serum clearance of 0.1 l/h/kg, a serum elimination halflife of about 1.1 h, and an apparent volume of distribution of 0.15 l/kg. 98% of pantoprazole is bound to serum proteins.",Pharmacokinetics of pantoprazole in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738854/),[l] / [kg],0.15,126647,DB00213,Pantoprazole
,8738854,half-life,"In patients with severe liver cirrhosis, the decreased rate of metabolism results in a half-life of 7-9 h.",Pharmacokinetics of pantoprazole in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738854/),h,7-9,126648,DB00213,Pantoprazole
,8738854,half-life,"The clearance of pantoprazole is only slightly affected by age, its half-life being approximately 1.25 h in the elderly.",Pharmacokinetics of pantoprazole in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738854/),h,1.25,126649,DB00213,Pantoprazole
,31316654,Retention times,"Retention times of pantoprazole and internal standard, lansoprazole was 4.1 and 6.0 min respectively.",A New Solid-Phase Extraction Method for Determination of Pantoprazole in Human Plasma Using High-Performance Liquid Chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31316654/),min,4.1,135200,DB00213,Pantoprazole
,31316654,Retention times,"Retention times of pantoprazole and internal standard, lansoprazole was 4.1 and 6.0 min respectively.",A New Solid-Phase Extraction Method for Determination of Pantoprazole in Human Plasma Using High-Performance Liquid Chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31316654/),min,6.0,135201,DB00213,Pantoprazole
,30520273,clearance (CL) ratio,The predicted-to-observed pantoprazole clearance (CL) ratio ranged from 0.96-1.35 in children 1-17 years of age and 0.43-0.70 in term infants.,Assessing CYP2C19 Ontogeny in Neonates and Infants Using Physiologically Based Pharmacokinetic Models: Impact of Enzyme Maturation Versus Inhibition. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30520273/),,0.96-1.35,135347,DB00213,Pantoprazole
,30520273,clearance (CL) ratio,The predicted-to-observed pantoprazole clearance (CL) ratio ranged from 0.96-1.35 in children 1-17 years of age and 0.43-0.70 in term infants.,Assessing CYP2C19 Ontogeny in Neonates and Infants Using Physiologically Based Pharmacokinetic Models: Impact of Enzyme Maturation Versus Inhibition. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30520273/),,0.43-0.70,135348,DB00213,Pantoprazole
,30520273,CL ratio,"The predicted-to-observed esomeprazole CL ratio ranged from 1.08-1.50 for children 6-17 years of age, and 0.15-0.33 for infants.",Assessing CYP2C19 Ontogeny in Neonates and Infants Using Physiologically Based Pharmacokinetic Models: Impact of Enzyme Maturation Versus Inhibition. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30520273/),,1.08-1.50,135349,DB00213,Pantoprazole
,30520273,CL ratio,"The predicted-to-observed esomeprazole CL ratio ranged from 1.08-1.50 for children 6-17 years of age, and 0.15-0.33 for infants.",Assessing CYP2C19 Ontogeny in Neonates and Infants Using Physiologically Based Pharmacokinetic Models: Impact of Enzyme Maturation Versus Inhibition. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30520273/),,0.15-0.33,135350,DB00213,Pantoprazole
,15831779,AUC(0-infinity),A decrease in the mean dabigatran AUC(0-infinity) (904 to 705 ng*h/mL) occurred with coadministration of pantoprazole.,Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831779/),[h·ng] / [ml],904 to 705,140325,DB00213,Pantoprazole
,9494064,serum AUC,"Actually, although 40 mg pantoprazole (steady state) gave a slightly higher serum AUC of the total parent compound than 40 mg omeprazole (10.5 vs.",Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9494064/),,10.5,141509,DB00213,Pantoprazole
,9494064,serum protein binding,"7.1 micromol x h x l[-1]), a higher serum protein binding of pantoprazole versus omeprazole (98 vs. 96%) reversed the AUC values for the free drug in favor of a lower value for pantoprazole (0.19 vs. 0.28 micromol x h x l[-1]).",Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9494064/),,96,141510,DB00213,Pantoprazole
,9494064,AUC,"7.1 micromol x h x l[-1]), a higher serum protein binding of pantoprazole versus omeprazole (98 vs. 96%) reversed the AUC values for the free drug in favor of a lower value for pantoprazole (0.19 vs. 0.28 micromol x h x l[-1]).",Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9494064/),[h·μM] / [l],0.19,141511,DB00213,Pantoprazole
,9494064,AUC,"7.1 micromol x h x l[-1]), a higher serum protein binding of pantoprazole versus omeprazole (98 vs. 96%) reversed the AUC values for the free drug in favor of a lower value for pantoprazole (0.19 vs. 0.28 micromol x h x l[-1]).",Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9494064/),[h·μM] / [l],0.28,141512,DB00213,Pantoprazole
,9494064,activation half-life,"At pH 5.1, the activation half-life of pantoprazole was 4.7 versus 1.4 h for omeprazole, the latter being in the order of the common serum elimination half-life determined in an intraindividual comparison (1.24 vs. 1.25 h).",Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9494064/),h,4.7,141513,DB00213,Pantoprazole
,9494064,activation half-life,"At pH 5.1, the activation half-life of pantoprazole was 4.7 versus 1.4 h for omeprazole, the latter being in the order of the common serum elimination half-life determined in an intraindividual comparison (1.24 vs. 1.25 h).",Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9494064/),h,1.4,141514,DB00213,Pantoprazole
,9494064,serum elimination half-life,"At pH 5.1, the activation half-life of pantoprazole was 4.7 versus 1.4 h for omeprazole, the latter being in the order of the common serum elimination half-life determined in an intraindividual comparison (1.24 vs. 1.25 h).",Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9494064/),h,1.24,141515,DB00213,Pantoprazole
,9494064,serum elimination half-life,"At pH 5.1, the activation half-life of pantoprazole was 4.7 versus 1.4 h for omeprazole, the latter being in the order of the common serum elimination half-life determined in an intraindividual comparison (1.24 vs. 1.25 h).",Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9494064/),h,1.25,141516,DB00213,Pantoprazole
,15313923,IC50,"In Sf9-BCRP vesicles, pantoprazole and omeprazole inhibited MTX transport (IC50 13 microm and 36 microm, respectively).",Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15313923/),μm,13,145395,DB00213,Pantoprazole
,15313923,IC50,"In Sf9-BCRP vesicles, pantoprazole and omeprazole inhibited MTX transport (IC50 13 microm and 36 microm, respectively).",Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15313923/),μm,36,145396,DB00213,Pantoprazole
,10471987,peak concentration (Cmax),"For cisapride alone, mean parameter values were the following: peak concentration (Cmax), 56 ng/mL; time to Cmax (tmax), 1.7 hours; area under the concentration-time curve (AUC), 426 ng x h/mL; and terminal half-life (t1/2), 5.8 hours.",Lack of pharmacokinetic interaction between oral pantoprazole and cisapride in healthy adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10471987/),[ng] / [ml],56,155744,DB00213,Pantoprazole
,10471987,time to Cmax (tmax),"For cisapride alone, mean parameter values were the following: peak concentration (Cmax), 56 ng/mL; time to Cmax (tmax), 1.7 hours; area under the concentration-time curve (AUC), 426 ng x h/mL; and terminal half-life (t1/2), 5.8 hours.",Lack of pharmacokinetic interaction between oral pantoprazole and cisapride in healthy adults. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10471987/),h,1.7,155745,DB00213,Pantoprazole
,10471987,area under the concentration-time curve (AUC),"For cisapride alone, mean parameter values were the following: peak concentration (Cmax), 56 ng/mL; time to Cmax (tmax), 1.7 hours; area under the concentration-time curve (AUC), 426 ng x h/mL; and terminal half-life (t1/2), 5.8 hours.",Lack of pharmacokinetic interaction between oral pantoprazole and cisapride in healthy adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10471987/),[h·ng] / [ml],426,155746,DB00213,Pantoprazole
,10471987,terminal half-life (t1/2),"For cisapride alone, mean parameter values were the following: peak concentration (Cmax), 56 ng/mL; time to Cmax (tmax), 1.7 hours; area under the concentration-time curve (AUC), 426 ng x h/mL; and terminal half-life (t1/2), 5.8 hours.",Lack of pharmacokinetic interaction between oral pantoprazole and cisapride in healthy adults. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10471987/),h,5.8,155747,DB00213,Pantoprazole
,32558923,turnover half-life,"Based on the recovery of R-pantoprazole oral clearance, the turnover half-life of CYP2C19 was estimated to average 53 hours.","Effect of High-Dose Esomeprazole on CYP1A2, CYP2C19, and CYP3A4 Activities in Humans: Evidence for Substantial and Long-lasting Inhibition of CYP2C19. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32558923/),h,53,159396,DB00213,Pantoprazole
,11210394,half-lives,Pantoprazole has short half-lives of 0.5 hours in rats and 0.8 hours in humans.,Pharmacodynamic modeling of pantoprazole's irreversible effect on gastric acid secretion in humans and rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210394/),h,0.5,160213,DB00213,Pantoprazole
,11210394,half-lives,Pantoprazole has short half-lives of 0.5 hours in rats and 0.8 hours in humans.,Pharmacodynamic modeling of pantoprazole's irreversible effect on gastric acid secretion in humans and rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210394/),h,0.8,160214,DB00213,Pantoprazole
,11210394,apparent reaction rate constants,"The apparent reaction rate constants of pantoprazole with the proton pumps were 0.691 L/mg/h in rats and 0.751 L/mg/h in humans, and the apparent recovery rates of the pumps were 0.053 h-1 and 0.031 h-1, respectively.",Pharmacodynamic modeling of pantoprazole's irreversible effect on gastric acid secretion in humans and rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210394/),[l] / [h·mg],0.691,160215,DB00213,Pantoprazole
,11210394,apparent reaction rate constants,"The apparent reaction rate constants of pantoprazole with the proton pumps were 0.691 L/mg/h in rats and 0.751 L/mg/h in humans, and the apparent recovery rates of the pumps were 0.053 h-1 and 0.031 h-1, respectively.",Pharmacodynamic modeling of pantoprazole's irreversible effect on gastric acid secretion in humans and rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210394/),[l] / [h·mg],0.751,160216,DB00213,Pantoprazole
,11210394,apparent recovery rates,"The apparent reaction rate constants of pantoprazole with the proton pumps were 0.691 L/mg/h in rats and 0.751 L/mg/h in humans, and the apparent recovery rates of the pumps were 0.053 h-1 and 0.031 h-1, respectively.",Pharmacodynamic modeling of pantoprazole's irreversible effect on gastric acid secretion in humans and rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210394/),1/[h],0.053,160217,DB00213,Pantoprazole
,11210394,apparent recovery rates,"The apparent reaction rate constants of pantoprazole with the proton pumps were 0.691 L/mg/h in rats and 0.751 L/mg/h in humans, and the apparent recovery rates of the pumps were 0.053 h-1 and 0.031 h-1, respectively.",Pharmacodynamic modeling of pantoprazole's irreversible effect on gastric acid secretion in humans and rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210394/),1/[h],0.031,160218,DB00213,Pantoprazole
,20306184,area under the plasma concentration versus time curve (AUC),"The popPK modeling of the pantoprazole 1.25 mg and 2.5 mg groups obtained mean (+/-standard deviation) estimates for the area under the plasma concentration versus time curve (AUC) of 3.54 (+/-2.82) and 7.27 (+/-5.30) microg h/mL, respectively, and mean estimates for half-life of 3.1 (+/-1.5) and 2.7 (+/-1.1) h, respectively.","Single-dose, multiple-dose, and population pharmacokinetics of pantoprazole in neonates and preterm infants with a clinical diagnosis of gastroesophageal reflux disease (GERD). ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20306184/),[h·μg] / [ml],3.54,164145,DB00213,Pantoprazole
,20306184,area under the plasma concentration versus time curve (AUC),"The popPK modeling of the pantoprazole 1.25 mg and 2.5 mg groups obtained mean (+/-standard deviation) estimates for the area under the plasma concentration versus time curve (AUC) of 3.54 (+/-2.82) and 7.27 (+/-5.30) microg h/mL, respectively, and mean estimates for half-life of 3.1 (+/-1.5) and 2.7 (+/-1.1) h, respectively.","Single-dose, multiple-dose, and population pharmacokinetics of pantoprazole in neonates and preterm infants with a clinical diagnosis of gastroesophageal reflux disease (GERD). ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20306184/),[h·μg] / [ml],7.27,164146,DB00213,Pantoprazole
,20306184,half-life,"The popPK modeling of the pantoprazole 1.25 mg and 2.5 mg groups obtained mean (+/-standard deviation) estimates for the area under the plasma concentration versus time curve (AUC) of 3.54 (+/-2.82) and 7.27 (+/-5.30) microg h/mL, respectively, and mean estimates for half-life of 3.1 (+/-1.5) and 2.7 (+/-1.1) h, respectively.","Single-dose, multiple-dose, and population pharmacokinetics of pantoprazole in neonates and preterm infants with a clinical diagnosis of gastroesophageal reflux disease (GERD). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20306184/),h,3.1,164147,DB00213,Pantoprazole
,20306184,half-life,"The popPK modeling of the pantoprazole 1.25 mg and 2.5 mg groups obtained mean (+/-standard deviation) estimates for the area under the plasma concentration versus time curve (AUC) of 3.54 (+/-2.82) and 7.27 (+/-5.30) microg h/mL, respectively, and mean estimates for half-life of 3.1 (+/-1.5) and 2.7 (+/-1.1) h, respectively.","Single-dose, multiple-dose, and population pharmacokinetics of pantoprazole in neonates and preterm infants with a clinical diagnosis of gastroesophageal reflux disease (GERD). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20306184/),h,2.7,164148,DB00213,Pantoprazole
,19969078,relative bioavailability,"The amount of drug absorbed after oral dosing was similar after reference or agglomerate administration, leading to a relative bioavailability of 108%.",Pharmacokinetics evaluation of soft agglomerates for prompt delivery of enteric pantoprazole-loaded microparticles. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19969078/),%,108,169464,DB00213,Pantoprazole
,19969078,absorption lag-time,The absorption lag-time was significantly reduced after agglomerate administration (from 135.5+/-50.6 to 15.0+/-2.5min).,Pharmacokinetics evaluation of soft agglomerates for prompt delivery of enteric pantoprazole-loaded microparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19969078/),min,135.5,169465,DB00213,Pantoprazole
,19969078,absorption lag-time,The absorption lag-time was significantly reduced after agglomerate administration (from 135.5+/-50.6 to 15.0+/-2.5min).,Pharmacokinetics evaluation of soft agglomerates for prompt delivery of enteric pantoprazole-loaded microparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19969078/),min,15.0,169466,DB00213,Pantoprazole
,16028623,Bioavailability,Bioavailability of intragastric-administered pantoprazole was 41%.,Pharmacokinetics and pharmacodynamics of pantoprazole in clinically normal neonatal foals. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028623/),%,41,170384,DB00213,Pantoprazole
,11768559,half-life,"Actually, all PPIs display chemical activation half-lives at pH 1.0 of a few minutes at the most, while being eliminated from serum with a half-life of about 1 h.",Relative efficacies of gastric proton-pump inhibitors on a milligram basis: desired and undesired SH reactions. Impact of chirality. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11768559/),h,1,175782,DB00213,Pantoprazole
,18972873,flow rate,"The separation was achieved on a monolithic silica column using acetonitrile-potassium dihydrogen phosphate buffer (25:75,v/v), pH 3.0, as the mobile phase at a flow rate of 1.5 ml min(-1).",A rapid high-performance liquid chromatographic method for the determination of pantoprazole in plasma using UV detection. Application in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18972873/),[ml] / [min],1.5,176276,DB00213,Pantoprazole
,11467632,time to the maximum observed concentration,"Lansoprazole's time to the maximum observed concentration and area under the plasma concentration-time curve over the 24-h time interval increased significantly from day I to day 5 (1.7 h vs 2.0 h and 1865 ng x h/ml vs 2091 ng x h/ml, respectively), and a significant increase in half-life relative to day 1 (0.96 h) was observed on day 5 (1.03 h) during pantoprazole treatment.",Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11467632/),h,1.7,177294,DB00213,Pantoprazole
,11467632,time to the maximum observed concentration,"Lansoprazole's time to the maximum observed concentration and area under the plasma concentration-time curve over the 24-h time interval increased significantly from day I to day 5 (1.7 h vs 2.0 h and 1865 ng x h/ml vs 2091 ng x h/ml, respectively), and a significant increase in half-life relative to day 1 (0.96 h) was observed on day 5 (1.03 h) during pantoprazole treatment.",Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11467632/),h,2.0,177295,DB00213,Pantoprazole
,11467632,area under the plasma concentration-time curve,"Lansoprazole's time to the maximum observed concentration and area under the plasma concentration-time curve over the 24-h time interval increased significantly from day I to day 5 (1.7 h vs 2.0 h and 1865 ng x h/ml vs 2091 ng x h/ml, respectively), and a significant increase in half-life relative to day 1 (0.96 h) was observed on day 5 (1.03 h) during pantoprazole treatment.",Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11467632/),[h·ng] / [ml],1865,177296,DB00213,Pantoprazole
,11467632,area under the plasma concentration-time curve,"Lansoprazole's time to the maximum observed concentration and area under the plasma concentration-time curve over the 24-h time interval increased significantly from day I to day 5 (1.7 h vs 2.0 h and 1865 ng x h/ml vs 2091 ng x h/ml, respectively), and a significant increase in half-life relative to day 1 (0.96 h) was observed on day 5 (1.03 h) during pantoprazole treatment.",Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11467632/),[h·ng] / [ml],2091,177297,DB00213,Pantoprazole
,11467632,half-life,"Lansoprazole's time to the maximum observed concentration and area under the plasma concentration-time curve over the 24-h time interval increased significantly from day I to day 5 (1.7 h vs 2.0 h and 1865 ng x h/ml vs 2091 ng x h/ml, respectively), and a significant increase in half-life relative to day 1 (0.96 h) was observed on day 5 (1.03 h) during pantoprazole treatment.",Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11467632/),h,0.96,177298,DB00213,Pantoprazole
,11467632,half-life,"Lansoprazole's time to the maximum observed concentration and area under the plasma concentration-time curve over the 24-h time interval increased significantly from day I to day 5 (1.7 h vs 2.0 h and 1865 ng x h/ml vs 2091 ng x h/ml, respectively), and a significant increase in half-life relative to day 1 (0.96 h) was observed on day 5 (1.03 h) during pantoprazole treatment.",Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11467632/),h,1.03,177299,DB00213,Pantoprazole
,16180125,CLint,"The sum of the CLint of the formation of all three metabolites was 3.06 and 4.82 mL/min/mg protein for S- and R-pantoprazole, respectively.",Pharmacokinetic differences between pantoprazole enantiomers in rats. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16180125/),[ml] / [mg·min],3.06,179016,DB00213,Pantoprazole
,16180125,CLint,"The sum of the CLint of the formation of all three metabolites was 3.06 and 4.82 mL/min/mg protein for S- and R-pantoprazole, respectively.",Pharmacokinetic differences between pantoprazole enantiomers in rats. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16180125/),[ml] / [mg·min],4.82,179017,DB00213,Pantoprazole
,19858252,apparent clearance,"A one-compartment model with first-order absorption and elimination as the basic structural model appropriately described the data, with the apparent clearance being 75.8 liters/h (95% confidence interval [CI], 65.2 to 86.4 liters/h) and the apparent volume being distribution of 835 liters (95% CI, 559 to 1,111 liters).",Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19858252/),[l] / [h],75.8,179515,DB00213,Pantoprazole
,19858252,apparent volume being distribution,"A one-compartment model with first-order absorption and elimination as the basic structural model appropriately described the data, with the apparent clearance being 75.8 liters/h (95% confidence interval [CI], 65.2 to 86.4 liters/h) and the apparent volume being distribution of 835 liters (95% CI, 559 to 1,111 liters).",Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19858252/),l,835,179516,DB00213,Pantoprazole
,19858252,volume of distribution,"Among the covariates tested, significant effects were found for age (decrease in the volume of distribution of 123 liters per year of age) and the presence of diarrhea (59% loss of bioavailability).",Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19858252/),l,123,179517,DB00213,Pantoprazole
,9803530,AUCs,"The AUCs of (-)-PAN after intravenous and oral dosing of (+)-PAN were 36.3 and 28.1%, respectively of those of total [(+) + (-)] PAN.",Stereoselective chiral inversion of pantoprazole enantiomers after separate doses to rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9803530/),%,36.3,180478,DB00213,Pantoprazole
,9803530,AUCs,"The AUCs of (-)-PAN after intravenous and oral dosing of (+)-PAN were 36.3 and 28.1%, respectively of those of total [(+) + (-)] PAN.",Stereoselective chiral inversion of pantoprazole enantiomers after separate doses to rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9803530/),%,28.1,180479,DB00213,Pantoprazole
,21294597,total clearance after oral administration (CL/F),"Population estimates of total clearance after oral administration (CL/F) and volume of distribution after oral administration (V(d)/F) were 7.92 L/h and 248 L, respectively.",Population pharmacokinetic evaluation with external validation and Bayesian estimator of voriconazole in liver transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21294597/),[l] / [h],7.92,182687,DB00213,Pantoprazole
,21294597,volume of distribution after oral administration (V(d)/F),"Population estimates of total clearance after oral administration (CL/F) and volume of distribution after oral administration (V(d)/F) were 7.92 L/h and 248 L, respectively.",Population pharmacokinetic evaluation with external validation and Bayesian estimator of voriconazole in liver transplant recipients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21294597/),l,248,182688,DB00213,Pantoprazole
,21294597,MPE,MPE was 0.206 μg/mL (not significantly different from zero) and MAPE was 0.99 μg/mL.,Population pharmacokinetic evaluation with external validation and Bayesian estimator of voriconazole in liver transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21294597/),[μg] / [ml],0.206,182689,DB00213,Pantoprazole
,21294597,MAPE,MPE was 0.206 μg/mL (not significantly different from zero) and MAPE was 0.99 μg/mL.,Population pharmacokinetic evaluation with external validation and Bayesian estimator of voriconazole in liver transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21294597/),[μg] / [ml],0.99,182690,DB00213,Pantoprazole
,26071277,Emax,"The relationship between inhibition of platelet aggregation (IPA, %) and the active metabolite AUC (h*μg/L) was described by a sigmoid function (Emax 56 ± 5%; EAUC50 15.9 ± 0.8 h*μg/L) with a gamma exponent (7.04 ± 2.26).","Omeprazole, pantoprazole, and CYP2C19 effects on clopidogrel pharmacokinetic-pharmacodynamic relationships in stable coronary artery disease patients. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26071277/),%,56,183118,DB00213,Pantoprazole
,26071277,EAUC50,"The relationship between inhibition of platelet aggregation (IPA, %) and the active metabolite AUC (h*μg/L) was described by a sigmoid function (Emax 56 ± 5%; EAUC50 15.9 ± 0.8 h*μg/L) with a gamma exponent (7.04 ± 2.26).","Omeprazole, pantoprazole, and CYP2C19 effects on clopidogrel pharmacokinetic-pharmacodynamic relationships in stable coronary artery disease patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26071277/),[h·μg] / [l],15.9,183119,DB00213,Pantoprazole
≧,31029803,relative recoveries,The LLOQ was 100 ng/mL and the relative recoveries were ≧ 73.2 ± 4.8%.,A new strategy for extraction and depuration of pantoprazole in rat plasma: Vortex assisted dispersive micro-solid-phase extraction employing metal organic framework MIL-101(Cr) as sorbent followed by dispersive liquid-liquid microextraction based on solidification of a floating organic droplet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31029803/),%,73.2,185094,DB00213,Pantoprazole
,29315506,time to reach steady state,"For voriconazole, time to reach steady state can vary from 5-7 days, not optimal for critically ill patients.",Optimization of Voriconazole Therapy for the Treatment of Invasive Fungal Infections in Adults. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29315506/),d,5-7,193341,DB00213,Pantoprazole
,25913040,dAUC,"MMF + PAN intake led to a lowest mean dAUC for MPA of 41.46 ng h ml(-1) mg(-1) [95% confidence interval (CI) 32.38, 50.54], while MPA exposure was highest for EC-MPS + PAN [dAUC: 46.30 ng h ml(-1) mg(-1) (95% CI 37.11, 55.49)].",No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25913040/),[h·ng] / [mg·ml],41.46,196144,DB00213,Pantoprazole
,25913040,dAUC,"MMF + PAN intake led to a lowest mean dAUC for MPA of 41.46 ng h ml(-1) mg(-1) [95% confidence interval (CI) 32.38, 50.54], while MPA exposure was highest for EC-MPS + PAN [dAUC: 46.30 ng h ml(-1) mg(-1) (95% CI 37.11, 55.49)].",No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25913040/),[h·ng] / [mg·ml],46.30,196145,DB00213,Pantoprazole
,25913040,dAUC,"Only for MMF [dAUC: 41.46 ng h ml(-1) mg(-1) (95% CI 32.38, 50.54)] and EC-MPS [dAUC: 43.39 ng h ml(-1) mg(-1) (95% CI 33.44, 53.34)] bioequivalence was established for dAUC [geometric mean ratio: 101.25% (90% CI 84.60, 121.17)].",No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25913040/),[h·ng] / [mg·ml],41.46,196146,DB00213,Pantoprazole
,25913040,dAUC,"Only for MMF [dAUC: 41.46 ng h ml(-1) mg(-1) (95% CI 32.38, 50.54)] and EC-MPS [dAUC: 43.39 ng h ml(-1) mg(-1) (95% CI 33.44, 53.34)] bioequivalence was established for dAUC [geometric mean ratio: 101.25% (90% CI 84.60, 121.17)].",No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25913040/),[h·ng] / [mg·ml],43.39,196147,DB00213,Pantoprazole
,25913040,time to Cmax (tmax),Simultaneous EC-MPS + PAN intake led to an earlier time to Cmax (tmax) [median: 2.0 h (min-max: 0.5-10.0)] than EC-MPS intake alone [3 h (1.5-12.0); P = 0.037].,No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25913040/),h,2.0,196148,DB00213,Pantoprazole
,25913040,time to Cmax (tmax),Simultaneous EC-MPS + PAN intake led to an earlier time to Cmax (tmax) [median: 2.0 h (min-max: 0.5-10.0)] than EC-MPS intake alone [3 h (1.5-12.0); P = 0.037].,No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25913040/),h,3,196149,DB00213,Pantoprazole
,25913040,Tmax,"Tmax was not affected for MMF [1.0 h (0.5-5.0)] ± pantoprazole [1.0 h (0.5-6.0), P = 0.928).",No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25913040/),h,1.0,196150,DB00213,Pantoprazole
,25913040,Tmax,"Tmax was not affected for MMF [1.0 h (0.5-5.0)] ± pantoprazole [1.0 h (0.5-6.0), P = 0.928).",No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25913040/),h,1.0,196151,DB00213,Pantoprazole
,15871633,time to reach maximum plasma concentration,"Like adults, PPIs are rapidly absorbed in children following oral administration; the mean time to reach maximum plasma concentration varies from 1 to 3 hours.",Pharmacokinetics of proton pump inhibitors in children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15871633/),h,1 to 3,196990,DB00213,Pantoprazole
,15871633,elimination half-lives,"PPIs are rapidly metabolised in children, with short elimination half-lives of around 1 hour, similar to that reported for adults.",Pharmacokinetics of proton pump inhibitors in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15871633/),h,1,196991,DB00213,Pantoprazole
,22418828,AUC,"Heterozygotes, i.e.. CYP2C19*1/*2 vs CYP2C19*1/*1 were characterized by higher AUC (4.38 ± 1.00 mg·h/L vs 3.00 ± 1.02 mg·h/L, p < 0.05) and C(max) (2.13 ± 0.42 mg/L vs 1.61 ± 0.35 mg/L, p < 0.05) respectively.",CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22418828/),[h·mg] / [l],4.38,197531,DB00213,Pantoprazole
,22418828,AUC,"Heterozygotes, i.e.. CYP2C19*1/*2 vs CYP2C19*1/*1 were characterized by higher AUC (4.38 ± 1.00 mg·h/L vs 3.00 ± 1.02 mg·h/L, p < 0.05) and C(max) (2.13 ± 0.42 mg/L vs 1.61 ± 0.35 mg/L, p < 0.05) respectively.",CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22418828/),[h·mg] / [l],3.00,197532,DB00213,Pantoprazole
,22418828,C(max),"Heterozygotes, i.e.. CYP2C19*1/*2 vs CYP2C19*1/*1 were characterized by higher AUC (4.38 ± 1.00 mg·h/L vs 3.00 ± 1.02 mg·h/L, p < 0.05) and C(max) (2.13 ± 0.42 mg/L vs 1.61 ± 0.35 mg/L, p < 0.05) respectively.",CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22418828/),[mg] / [l],2.13,197533,DB00213,Pantoprazole
,22418828,C(max),"Heterozygotes, i.e.. CYP2C19*1/*2 vs CYP2C19*1/*1 were characterized by higher AUC (4.38 ± 1.00 mg·h/L vs 3.00 ± 1.02 mg·h/L, p < 0.05) and C(max) (2.13 ± 0.42 mg/L vs 1.61 ± 0.35 mg/L, p < 0.05) respectively.",CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22418828/),[mg] / [l],1.61,197534,DB00213,Pantoprazole
,22418828,MRT,"A significant reduction in MRT (3.83 ± 0.82 h vs 2.73 ± 0.23 h, p < 0.05) in carriers of CYP2C19*17/*17 vs CYP2C19*1/*1 genotypes was observed.",CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22418828/),h,3.83,197535,DB00213,Pantoprazole
,22418828,MRT,"A significant reduction in MRT (3.83 ± 0.82 h vs 2.73 ± 0.23 h, p < 0.05) in carriers of CYP2C19*17/*17 vs CYP2C19*1/*1 genotypes was observed.",CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22418828/),h,2.73,197536,DB00213,Pantoprazole
,22418828,population oral clearance,The lowest population oral clearance was assessed in the carriers of genotype *2/*2 (3.68 L/h) and the highest value in subjects with genotype *17/*17 (31.13 L/h).,CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22418828/),[l] / [h],3.68,197537,DB00213,Pantoprazole
,22418828,population oral clearance,The lowest population oral clearance was assessed in the carriers of genotype *2/*2 (3.68 L/h) and the highest value in subjects with genotype *17/*17 (31.13 L/h).,CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22418828/),[l] / [h],31.13,197538,DB00213,Pantoprazole
,23512128,half-life,"After irreversible chemical inhibition of the proton pump, such as occurs with pantoprazole, the recovery of the protein of the pump has a half-life of around 50 h.","Proton pump inhibitors in pediatrics : mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23512128/),h,50,198226,DB00213,Pantoprazole
,24246350,area under the curve [AUC]0-4h,"Pharmacokinetic indices showed better and faster absorption for the soft gel capsule versus tablet (area under the curve [AUC]0-4h = 16,240 vs.",Tablet levothyroxine (L-T4) malabsorption induced by proton pump inhibitor; a problem that was solved by switching to L-T4 in soft gel capsule. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24246350/),,"16,240",214754,DB00213,Pantoprazole
,24246350,maximum absorption [Cmax],"10,960 nmol/L x 4 hours, maximum absorption [Cmax] = 108 vs. 73 nmol/L, and time of maximum absorption [Tmax] = 120 minutes vs. 180 minutes).",Tablet levothyroxine (L-T4) malabsorption induced by proton pump inhibitor; a problem that was solved by switching to L-T4 in soft gel capsule. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24246350/),[nM] / [l],108,214755,DB00213,Pantoprazole
,24246350,maximum absorption [Cmax],"10,960 nmol/L x 4 hours, maximum absorption [Cmax] = 108 vs. 73 nmol/L, and time of maximum absorption [Tmax] = 120 minutes vs. 180 minutes).",Tablet levothyroxine (L-T4) malabsorption induced by proton pump inhibitor; a problem that was solved by switching to L-T4 in soft gel capsule. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24246350/),[nM] / [l],73,214756,DB00213,Pantoprazole
,24246350,time of maximum absorption [Tmax],"10,960 nmol/L x 4 hours, maximum absorption [Cmax] = 108 vs. 73 nmol/L, and time of maximum absorption [Tmax] = 120 minutes vs. 180 minutes).",Tablet levothyroxine (L-T4) malabsorption induced by proton pump inhibitor; a problem that was solved by switching to L-T4 in soft gel capsule. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24246350/),min,120,214757,DB00213,Pantoprazole
,24246350,time of maximum absorption [Tmax],"10,960 nmol/L x 4 hours, maximum absorption [Cmax] = 108 vs. 73 nmol/L, and time of maximum absorption [Tmax] = 120 minutes vs. 180 minutes).",Tablet levothyroxine (L-T4) malabsorption induced by proton pump inhibitor; a problem that was solved by switching to L-T4 in soft gel capsule. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24246350/),min,180,214758,DB00213,Pantoprazole
,17688075,f2,The sameness of the dissolution curves was assessed by f2 values between 50 and 100.,Bioequivalence of two enteric coated formulations of pantoprazole in healthy volunteers under fasting and fed conditions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17688075/),,50 and 100,215873,DB00213,Pantoprazole
higher,17688075,f2,"The postprandial study demonstrated a high intra-subject variability and in some subjects pantoprazole could not be detected for up to 24 h, although the dissolution profile of reference and test formulations presented a similar disposition in FaSSIF and FeSSIF as confirmed by the values of f2 higher than 50.",Bioequivalence of two enteric coated formulations of pantoprazole in healthy volunteers under fasting and fed conditions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17688075/),,50,215874,DB00213,Pantoprazole
,28452843,trough level,"There were significant differences in dabigatran trough level comparing patients treated with PPI and patients without PPI (58.86 ± 36.76 ng/mL vs. 110.72 ± 88.47 ng/mL, P < 0.05).",The Impact of Proton Pump Inhibition on Dabigatran Levels in Patients With Atrial Fibrillation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28452843/),[ng] / [ml],58.86,229739,DB00213,Pantoprazole
,28452843,trough level,"There were significant differences in dabigatran trough level comparing patients treated with PPI and patients without PPI (58.86 ± 36.76 ng/mL vs. 110.72 ± 88.47 ng/mL, P < 0.05).",The Impact of Proton Pump Inhibition on Dabigatran Levels in Patients With Atrial Fibrillation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28452843/),[ng] / [ml],110.72,229740,DB00213,Pantoprazole
,28452843,peak level,"Similarly, there were significant differences in dabigatran peak level between compared groups (88.0 ± 20.5 ng/mL vs. 174.4 ± 139.64 ng/mL, P < 0.05).",The Impact of Proton Pump Inhibition on Dabigatran Levels in Patients With Atrial Fibrillation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28452843/),[ng] / [ml],88.0,229741,DB00213,Pantoprazole
,28452843,peak level,"Similarly, there were significant differences in dabigatran peak level between compared groups (88.0 ± 20.5 ng/mL vs. 174.4 ± 139.64 ng/mL, P < 0.05).",The Impact of Proton Pump Inhibition on Dabigatran Levels in Patients With Atrial Fibrillation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28452843/),[ng] / [ml],174.4,229742,DB00213,Pantoprazole
,29656083,flow rate,"An Agilent C18 column (100 mm × 3 mm, 3.5 μm) was performed for chromatographic separation with the mobile phase composed of methanol-water (containing formic acid) at a flow rate of 0.4 mL/min.","Rapid determination of 3', 4'-dimethoxy flavonol-3-β-d-glucopyranoside in rat plasma by LC-MS/MS method followed by protein precipitation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29656083/),[ml] / [min],0.4,235912,DB00213,Pantoprazole
,29656083,m/z,"The MRM precursor-product ion transition of DF3G and Pantoprazole (IS) were m/z 461.1 → 299.2 and 383.9 → 200.2, respectively.","Rapid determination of 3', 4'-dimethoxy flavonol-3-β-d-glucopyranoside in rat plasma by LC-MS/MS method followed by protein precipitation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29656083/),,461.1,235913,DB00213,Pantoprazole
,29656083,m/z,"The MRM precursor-product ion transition of DF3G and Pantoprazole (IS) were m/z 461.1 → 299.2 and 383.9 → 200.2, respectively.","Rapid determination of 3', 4'-dimethoxy flavonol-3-β-d-glucopyranoside in rat plasma by LC-MS/MS method followed by protein precipitation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29656083/),,299.2,235914,DB00213,Pantoprazole
,29656083,m/z,"The MRM precursor-product ion transition of DF3G and Pantoprazole (IS) were m/z 461.1 → 299.2 and 383.9 → 200.2, respectively.","Rapid determination of 3', 4'-dimethoxy flavonol-3-β-d-glucopyranoside in rat plasma by LC-MS/MS method followed by protein precipitation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29656083/),,383.9,235915,DB00213,Pantoprazole
,29656083,m/z,"The MRM precursor-product ion transition of DF3G and Pantoprazole (IS) were m/z 461.1 → 299.2 and 383.9 → 200.2, respectively.","Rapid determination of 3', 4'-dimethoxy flavonol-3-β-d-glucopyranoside in rat plasma by LC-MS/MS method followed by protein precipitation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29656083/),,200.2,235916,DB00213,Pantoprazole
,26567730,free fractions,"In the rat plasma, 60%±5.2% of 10-OH-NBP was unbound to proteins versus only 22%±2.3% of 3-OH-NBP being unbound, whereas in the rat brain, free fractions of 3-OH-NBP and 10-OH-NBP were 100%±9.7% and 49.9%±14.1%, respectively.","Isomer-selective distribution of 3-n-butylphthalide (NBP) hydroxylated metabolites, 3-hydroxy-NBP and 10-hydroxy-NBP, across the rat blood-brain barrier. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26567730/),%,100,236404,DB00213,Pantoprazole
,26567730,free fractions,"In the rat plasma, 60%±5.2% of 10-OH-NBP was unbound to proteins versus only 22%±2.3% of 3-OH-NBP being unbound, whereas in the rat brain, free fractions of 3-OH-NBP and 10-OH-NBP were 100%±9.7% and 49.9%±14.1%, respectively.","Isomer-selective distribution of 3-n-butylphthalide (NBP) hydroxylated metabolites, 3-hydroxy-NBP and 10-hydroxy-NBP, across the rat blood-brain barrier. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26567730/),%,49.9,236405,DB00213,Pantoprazole
,33330703,plasma clearance,"Results: Following IV administration, plasma clearance, elimination half-life, and volume of distribution of pantoprazole were estimated at 4.46 mL/kg/min, 2.81 h, and 0.301 L/kg, respectively.",Pharmacokinetics and Tissue Levels of Pantoprazole in Neonatal Calves After Intravenous Administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33330703/),[ml] / [kg·min],4.46,240973,DB00213,Pantoprazole
,33330703,elimination half-life,"Results: Following IV administration, plasma clearance, elimination half-life, and volume of distribution of pantoprazole were estimated at 4.46 mL/kg/min, 2.81 h, and 0.301 L/kg, respectively.",Pharmacokinetics and Tissue Levels of Pantoprazole in Neonatal Calves After Intravenous Administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33330703/),h,2.81,240974,DB00213,Pantoprazole
,33330703,volume of distribution,"Results: Following IV administration, plasma clearance, elimination half-life, and volume of distribution of pantoprazole were estimated at 4.46 mL/kg/min, 2.81 h, and 0.301 L/kg, respectively.",Pharmacokinetics and Tissue Levels of Pantoprazole in Neonatal Calves After Intravenous Administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33330703/),[l] / [kg],0.301,240975,DB00213,Pantoprazole
,33330703,global extraction ratio,The global extraction ratio was estimated at 0.053 ± 0.015.,Pharmacokinetics and Tissue Levels of Pantoprazole in Neonatal Calves After Intravenous Administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33330703/),,0.053,240976,DB00213,Pantoprazole
>,32516810,area,"A multicentre, randomized, prospective, double-blind placebo-controlled cross-over study was conducted to determine the effect of the PPI pantoprazole on the MPA and its metabolite MPA-glucuronide (MPA-G) area under the curve (AUC) >12 h (MPA-AUC12 h) in recipients maintained on mycophenolate mofetil (MMF) or enteric-coated mycophenolate sodium (EC-MPS).",Effect of the proton-pump Inhibitor pantoprazole on MycoPhenolic ACid exposure in kidney and liver transplant recipienTs (IMPACT study): a randomized trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32516810/),,12,242314,DB00213,Pantoprazole
,32516810,AUC12 h,"For recipients on MMF, there was a significant reduction in the MPA-AUC12 h [geometric mean (95% confidence interval) placebo: 53.9 (44.0-65.9) mg*h/L versus pantoprazole: 43.8 (35.6-53.4) mg*h/L; P = 0.004] when pantoprazole was co-administered compared with placebo.",Effect of the proton-pump Inhibitor pantoprazole on MycoPhenolic ACid exposure in kidney and liver transplant recipienTs (IMPACT study): a randomized trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32516810/),[h·mg] / [l],53.9,242315,DB00213,Pantoprazole
,32516810,AUC12 h,"For recipients on MMF, there was a significant reduction in the MPA-AUC12 h [geometric mean (95% confidence interval) placebo: 53.9 (44.0-65.9) mg*h/L versus pantoprazole: 43.8 (35.6-53.4) mg*h/L; P = 0.004] when pantoprazole was co-administered compared with placebo.",Effect of the proton-pump Inhibitor pantoprazole on MycoPhenolic ACid exposure in kidney and liver transplant recipienTs (IMPACT study): a randomized trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32516810/),[h·mg] / [l],43.8,242316,DB00213,Pantoprazole
,32516810,AUC12 h,"In contrast, co-administration with pantoprazole significantly increased MPA-AUC12 h [placebo: 36.1 (26.5-49.2) mg*h/L versus pantoprazole: 45.9 (35.5-59.3) mg*h/L; P = 0.023] in those receiving EC-MPS.",Effect of the proton-pump Inhibitor pantoprazole on MycoPhenolic ACid exposure in kidney and liver transplant recipienTs (IMPACT study): a randomized trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32516810/),[h·mg] / [l],36.1,242317,DB00213,Pantoprazole
,32516810,AUC12 h,"In contrast, co-administration with pantoprazole significantly increased MPA-AUC12 h [placebo: 36.1 (26.5-49.2) mg*h/L versus pantoprazole: 45.9 (35.5-59.3) mg*h/L; P = 0.023] in those receiving EC-MPS.",Effect of the proton-pump Inhibitor pantoprazole on MycoPhenolic ACid exposure in kidney and liver transplant recipienTs (IMPACT study): a randomized trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32516810/),[h·mg] / [l],45.9,242318,DB00213,Pantoprazole
more,21302042,extractive recovery,The extractive recovery of pantoprazole from the biological matrix was more than 77.58% and the matrix effect was complied with relevant provision.,Quantification of pantoprazole in human plasma using LC-MS/MS for pharmacokinetics and bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21302042/),%,77.58,243500,DB00213,Pantoprazole
,21302041,mass transitions,"The mass transitions are m/z 373.4→305.3 and 384.1→200.0 for finasteride and pantoprazole, respectively.",Determination of finasteride in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry with flow rate gradient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21302041/),,373.4,247570,DB00213,Pantoprazole
,21302041,mass transitions,"The mass transitions are m/z 373.4→305.3 and 384.1→200.0 for finasteride and pantoprazole, respectively.",Determination of finasteride in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry with flow rate gradient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21302041/),,384.1,247571,DB00213,Pantoprazole
,21302041,m/z,"The mass transitions are m/z 373.4→305.3 and 384.1→200.0 for finasteride and pantoprazole, respectively.",Determination of finasteride in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry with flow rate gradient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21302041/),,373.4,247572,DB00213,Pantoprazole
,21302041,m/z,"The mass transitions are m/z 373.4→305.3 and 384.1→200.0 for finasteride and pantoprazole, respectively.",Determination of finasteride in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry with flow rate gradient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21302041/),,305.3,247573,DB00213,Pantoprazole
,21302041,m/z,"The mass transitions are m/z 373.4→305.3 and 384.1→200.0 for finasteride and pantoprazole, respectively.",Determination of finasteride in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry with flow rate gradient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21302041/),,384.1,247574,DB00213,Pantoprazole
,21302041,m/z,"The mass transitions are m/z 373.4→305.3 and 384.1→200.0 for finasteride and pantoprazole, respectively.",Determination of finasteride in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry with flow rate gradient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21302041/),,200.0,247575,DB00213,Pantoprazole
,21302041,run time,The method had a run time of 3.6 min and a linear calibration curve at a range of 0.2-100 ng mL(-1) (r2=0.9958).,Determination of finasteride in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry with flow rate gradient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21302041/),min,3.6,247576,DB00213,Pantoprazole
more,21302041,extraction recoveries,"The extraction recoveries of finasteride from the biological matrix were more than 82.7%, and the intra- and inter-day precision of the assay at four concentrations were 2.4-8.0% with an accuracy of 94.3-105.8%.",Determination of finasteride in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry with flow rate gradient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21302041/),%,82.7,247577,DB00213,Pantoprazole
,11413863,Tmax,Tmax of crushed pantoprazole was earlier as compared to the intact tablet (0.5 h vs. 3 h) and Cmax was approximately 10% higher due to faster absorption.,Bioavailability of a crushed pantoprazole tablet after buffering with sodium hydrogencarbonate or magaldrate relative to the intact enteric coated pantoprazole tablet. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11413863/),h,0.5,247800,DB00213,Pantoprazole
,11413863,Tmax,Tmax of crushed pantoprazole was earlier as compared to the intact tablet (0.5 h vs. 3 h) and Cmax was approximately 10% higher due to faster absorption.,Bioavailability of a crushed pantoprazole tablet after buffering with sodium hydrogencarbonate or magaldrate relative to the intact enteric coated pantoprazole tablet. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11413863/),h,3,247801,DB00213,Pantoprazole
,11413863,bioavailability,"The bioavailability of the crushed pantoprazole tablet relative to the intact pantoprazole tablet was 93% when using sodium hydrogencarbonate as the buffering agent, and 88% when using magaldrate.",Bioavailability of a crushed pantoprazole tablet after buffering with sodium hydrogencarbonate or magaldrate relative to the intact enteric coated pantoprazole tablet. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11413863/),%,93,247802,DB00213,Pantoprazole
,11413863,bioavailability,"The bioavailability of the crushed pantoprazole tablet relative to the intact pantoprazole tablet was 93% when using sodium hydrogencarbonate as the buffering agent, and 88% when using magaldrate.",Bioavailability of a crushed pantoprazole tablet after buffering with sodium hydrogencarbonate or magaldrate relative to the intact enteric coated pantoprazole tablet. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11413863/),%,88,247803,DB00213,Pantoprazole
,8793599,absolute bioavailability,Its absolute bioavailability is 77% and does not change upon multiple dosing.,Pharmacokinetics of pantoprazole in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8793599/),%,77,251776,DB00213,Pantoprazole
,8793599,Cmax,"Following a single oral dose of 40 mg, Cmax is approximately 2.5 mg/l, with a tmax of 2-3 h.",Pharmacokinetics of pantoprazole in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8793599/),[mg] / [l],2.5,251777,DB00213,Pantoprazole
,8793599,tmax,"Following a single oral dose of 40 mg, Cmax is approximately 2.5 mg/l, with a tmax of 2-3 h.",Pharmacokinetics of pantoprazole in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8793599/),h,2-3,251778,DB00213,Pantoprazole
,8793599,AUC(0,"The AUC(0,inf.) is approximately 5 mgxh/l.",Pharmacokinetics of pantoprazole in man. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8793599/),[h·mg] / [l],5,251779,DB00213,Pantoprazole
,8793599,total serum clearance,"Pantoprazole is extensively metabolized in the liver, has a total serum clearance of 0.1 l/h/kg, a serum elimination half-life of about 1.1 h, and an apparent volume of distribution of 0.15 l/kg. 98% of pantoprazole is bound to serum proteins.",Pharmacokinetics of pantoprazole in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8793599/),[l] / [h·kg],0.1,251780,DB00213,Pantoprazole
,8793599,serum elimination half-life,"Pantoprazole is extensively metabolized in the liver, has a total serum clearance of 0.1 l/h/kg, a serum elimination half-life of about 1.1 h, and an apparent volume of distribution of 0.15 l/kg. 98% of pantoprazole is bound to serum proteins.",Pharmacokinetics of pantoprazole in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8793599/),h,1.1,251781,DB00213,Pantoprazole
,8793599,apparent volume of distribution,"Pantoprazole is extensively metabolized in the liver, has a total serum clearance of 0.1 l/h/kg, a serum elimination half-life of about 1.1 h, and an apparent volume of distribution of 0.15 l/kg. 98% of pantoprazole is bound to serum proteins.",Pharmacokinetics of pantoprazole in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8793599/),[l] / [kg],0.15,251782,DB00213,Pantoprazole
,8793599,half-life,"In patients with severe liver cirrhosis, the decreased rate of metabolism results in a half-life of 7-9 h.",Pharmacokinetics of pantoprazole in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8793599/),h,7-9,251783,DB00213,Pantoprazole
,8793599,half-life,"The clearance of pantoprazole is only slightly affected by age, its half-life being approximately 1.25 h in the elderly.",Pharmacokinetics of pantoprazole in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8793599/),h,1.25,251784,DB00213,Pantoprazole
,20456825,flow rate,"Following a single step liquid-liquid extraction analytes along with an internal standard (IS) were separated using an isocratic mobile phase of phosphate buffer (10 mM)/acetonitrile (53/47, v/v adjusted pH to 7.3 with triethylamine) at flow rate of 1 mL/min on reverse phase TRACER EXCEL 120 ODS-A column at room temperature.","Improved HPLC method for determination of four PPIs, omeprazole, pantoprazole, lansoprazole and rabeprazole in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20456825/),[ml] / [min],1,253824,DB00213,Pantoprazole
,20456825,Total analytical run time,Total analytical run time for selected PPIs was 10 min.,"Improved HPLC method for determination of four PPIs, omeprazole, pantoprazole, lansoprazole and rabeprazole in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20456825/),min,10,253825,DB00213,Pantoprazole
greater,20456825,recovery of,The recovery of method was equal or greater than 80% and lower limit of quantification (LLOQ) was 20 ng/mL for four PPIs.,"Improved HPLC method for determination of four PPIs, omeprazole, pantoprazole, lansoprazole and rabeprazole in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20456825/),%,80,253826,DB00213,Pantoprazole
,19360758,flow rate,"The baseline separation of all the peaks was achieved with 0.1% triethylamine (pH 6.0):acetonitrile (72:28, v/v) at a flow rate of 1 mL/min on a Zorbax C(8) column.","Simultaneous estimation of four proton pump inhibitors--lansoprazole, omeprazole, pantoprazole and rabeprazole: development of a novel generic HPLC-UV method and its application to clinical pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19360758/),[ml] / [min],1,262031,DB00213,Pantoprazole
,19360758,total chromatographic run time,"The total chromatographic run time was 11.0 min and the simultaneous elution of IS, OPZ, RPZ, PPZ and LPZ occurred at approximately 2.42, 4.45, 5.02 and 9.37 min, respectively.","Simultaneous estimation of four proton pump inhibitors--lansoprazole, omeprazole, pantoprazole and rabeprazole: development of a novel generic HPLC-UV method and its application to clinical pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19360758/),min,11.0,262032,DB00213,Pantoprazole
,19360758,total chromatographic run time,"The total chromatographic run time was 11.0 min and the simultaneous elution of IS, OPZ, RPZ, PPZ and LPZ occurred at approximately 2.42, 4.45, 5.02 and 9.37 min, respectively.","Simultaneous estimation of four proton pump inhibitors--lansoprazole, omeprazole, pantoprazole and rabeprazole: development of a novel generic HPLC-UV method and its application to clinical pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19360758/),min,2.42,262033,DB00213,Pantoprazole
,19360758,total chromatographic run time,"The total chromatographic run time was 11.0 min and the simultaneous elution of IS, OPZ, RPZ, PPZ and LPZ occurred at approximately 2.42, 4.45, 5.02 and 9.37 min, respectively.","Simultaneous estimation of four proton pump inhibitors--lansoprazole, omeprazole, pantoprazole and rabeprazole: development of a novel generic HPLC-UV method and its application to clinical pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19360758/),min,5.02,262034,DB00213,Pantoprazole
,19173681,CL,"In the final population model, the estimated CL and V(c) were 5.28 l h(-1) and 2.22 l, respectively, for a typical 5-year-old child weighing 20 kg.",Population pharmacokinetics of intravenous pantoprazole in paediatric intensive care patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19173681/),[l] / [h],5.28,266836,DB00213,Pantoprazole
,19173681,V(c),"In the final population model, the estimated CL and V(c) were 5.28 l h(-1) and 2.22 l, respectively, for a typical 5-year-old child weighing 20 kg.",Population pharmacokinetics of intravenous pantoprazole in paediatric intensive care patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19173681/),l,2.22,266837,DB00213,Pantoprazole
,18076218,t((1/2)),"With twice-daily administration of dabigatran etexilate, plasma concentrations of dabigatran reached steady state within 2-3 days, which is consistent with a t((1/2)) of 12-14 hours.",Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18076218/),h,12-14,270041,DB00213,Pantoprazole
,18076218,peak plasma concentrations,"The mean (SD) peak plasma concentrations on day 4 of treatment in male and female elderly subjects were 256 ng/mL (21.8) and 255 ng/mL (84.0), respectively.",Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18076218/),[ng] / [ml],256,270042,DB00213,Pantoprazole
,18076218,peak plasma concentrations,"The mean (SD) peak plasma concentrations on day 4 of treatment in male and female elderly subjects were 256 ng/mL (21.8) and 255 ng/mL (84.0), respectively.",Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18076218/),[ng] / [ml],255,270043,DB00213,Pantoprazole
,23350044,elimination half-life,PPIs have about 1hour of elimination half-life.,Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23350044/),h,1,271438,DB00213,Pantoprazole
,12973371,bioavailability,"Pantoprazole, a second-generation proton pump inhibitor, is absorbed after oral administration as enteric-coated tablet with maximum plasma concentrations within 2-3 h and a bioavailability of 77%.",Pharmacokinetics and metabolism of the proton pump inhibitor pantoprazole in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12973371/),%,77,272764,DB00213,Pantoprazole
,12973371,half-life,"The pharmacokinetic profile is practically unchanged after multiple dosing, as is expected for a drug with a short half-life of about 1 h.",Pharmacokinetics and metabolism of the proton pump inhibitor pantoprazole in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12973371/),h,1,272765,DB00213,Pantoprazole
